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Inflammation is a nonspecific, restorative response of tissues to injury The nature of 
the primary challenge to inflammation may vary considerably, including chemical or 
physical trauma, microbial infection, and ultraviolet radiation At the onset of the 
process of inflammation a large number of homeostatic mechanisms are altered m 
proportion to the magnitude of the mcitmg injury or infection The inflammatory 
process is set into motion by mediators that cause local vasodilatation and mcreased 
permeability of blood vessels These events are responsible for the redness, swelling and 
pain, the classical characteristic signs of inflammation In cutaneous inflammation 
mediators are, m part, derived from activated keratinocytes1 The role and 
characteristics of the currently known inflammatory mediators which play a role m 
cutaneous inflammation were recently reviewed by van Ruissen et al and by 
Schroder Activated keratinocytes may produce several mediators, including IL-1, IL-
6, IL-8, TNF-a, and IF-γ, which promote directional migration of inflammatory cells 
towards the site of inflammation4 and activation of leukocyte function m situ5 This 
migration can result in an accumulation of inflammatory cells such as macrophages, 
lymphocytes, and neutrophils6 Once arrived at the site of inflammation, activated 
neutrophils and macrophages release protemases such as elastase and cathepsin G by 
degranulation7 In this destructive phase (stage 1) the initiating stimulus is counteracted 
and the released proteinases serve to facilitate migration of neutrophils and 
macrophages, digest and remove necrotic tissues, and sometimes act as an antimicrobial 
agent Several locally synthesized inflammatory mediators may eventually diffuse mto 
the circulation and untiate a systemic reaction (stage 2) A well known systemic 
reaction to inflammation is the acute phase response8 9, which consists of an array of 
changes such as fever, activation of clotting, complement, kinin-forming and 
fibrinolytic pathways Additionally, the rate of synthesis of a number of liver proteins is 
altered These proteins, which are collectively known as acute phase reactants, form a 
group of functionally heterologous protems The plasma concentration of proteins such 
as a-1 -antitrypsin, a-1 -antichymotrypsin, and fibrinogen, which are consumed during 
inflammatory processes, is strongly increased during the acute phase It is thought that 
the enhanced synthesis of proteinase inhibitors such as a-1-antitrypsin provides a 
negative feedback mechanism to protect affected tissue against excessive proteolysis by 
polymorphonuclear leukocyte(PMN)/monocyte-denved proteinases like elastase, 
proteinase-3 and cathepsin G Resolution of an inflammatory episode may be due, in 
part, to modulation of stimulated or activated macrophages by proteinase inhibitors and 
other acute phase protems This phase (stage 3) leads to a gradual cessation of the 
inflammatory reaction The final phase, m which restoration of damaged tissue takes 
place (stage 4), requires the coordinated participation of inflammatory cells other than 
11 
Chapter 1 
PMNs, namely endothelial cells, fibroblasts, and lymphocytes In this phase 
hyperproliferation plays a significant role. Under normal physiologic conditions the 
preinflammatory state of physiologic equilibrium is restored once the inflammatory 
cycle is broken. If, however, for some reason the preinflammatory state of physiologic 
equilibrium cannot be restored, e.g. when antigen deposition or autoimmunity is the 
initiating stimulus of the inflammation, then failure to eliminate inducing agents results 
in chronic inflammation. 
Proteinases and their inhibitors 
Several inflammatory cells such as monocytes and PMNs can release reactive 
oxygen metabolites and proteolytic enzymes with the potential of severe tissue 
destruction1011. The destructive potential of these molecules can act as a defense 
mechanism against the environment, i.e. bacterial and fungal infection, but it can also 
be directed against tissue of the organism itself. A major serine proteinase derived from 
polymorphonuclear leukocytes is human leukocyte elastase12 When secreted at sites of 
inflammation this enzyme can cause severe tissue damage, since it is active at neutral pH and 
can degrade a broad range of connective tissue components such as elastin13, proteoglycans14 
and collagen1516. PMNs contain approximately 3 pg elastase per cell17, resulting in a daily 
turnover in the adult human body of more than 250 mg elastase18. 
Other elastases or elastase-like proteolytic enzymes have been found in different cell 
types such as monocytes, eosinophils, basophils, and mast cells19"21. Proteinase 3 is a 
human neutrophil derived serine proteinase with a substrate specificity very similar to 
that of human leukocyte elastase22. This enzyme was shown to be the target antigen of 
anti-neutrophil cytoplasm auto-antibodies associated with Wegener's granulomatosis23 
and it can induce emphysema in hamsters. 
Several inflammatory proteinases that diffuse from the site of inflammation into the 
surrounding tissue may attack normal tissue proteins resulting in tissue destruction. A 
balanced homeostatic control of the activity of proteinases is therefore essential to 
prevent unwanted proteolytic tissue destruction. Three principal in vivo mechanisms for 
homeostatic control are known12,24,25. First, compartmentalization of enzymes by 
membranes provides a way to store injurious agents and prevents damage of tissues. 
Second, enzymes may be secreted in latent, inactive forms that require activation to 
degrade proteins, as is the case for metalloproteinases and most of the serine 
proteinases and cysteine proteinases. Third, proteinase inhibitors exist to act as 
regulatory elements that counteract proteolytic activity by forming an inactive complex 
with their target proteinases. Most proteinase inhibitors are rather specific for their target 
proteinases, such as the inhibitors for the serine proteinases of the complement system, the 
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coagulation system and the the fibrinolytic system Some proteinase inhibitors can inhibit a 
broad spectrum of target proteinases such as alpha-2-macroglobulin that inhibits proteinases 
from various classes, and the tissue inhibitors of metalloproteinases (TIMPs) that inhibit 
various types of metalloproteinases Most of the proteinase inhibitors mentioned above are 
present in plasma and interstitial fluids26 A limited number of inhibitors is locally produced 
at the tissue level A crucial role for proteinases and their inhibitors has been suggested for 
several pathologic conditions, such as emphysema1327, arthritis1428, nephritis29, and certain 
skin diseases3031 
Skin-derived antileukoproteinase (SKALP) 
In 1987 our group observed mduction of an elastase inhibiting activity in normal 
human skin as a response to standardized injury of the epidermis by tapestnpping32 
This anti-elastase activity was later found to be present m several scaling skin 
disorders33 Activity of this inhibitor was shown to be high in psoriatic scales which were 
used as a convenient source for purification of this molecule with an estimated molecular 
mass of 11 kilodalton (kDa) on sodium dodecyl sulphate Polyacrylamide gel electrophoresis 
(SDS-PAGE)3435 Based on partial similarities with another locally synthesized inhibitor, 
known as antileukoproteiriase (ALP), which is also described as secretory leukocyte 
proteinase inhibitor (SLPI) or mucus proteinase inhibitor (MPI)36"38, we named this 
molecule skin-denved antileukoproteinase (SKALP) In cultured human keratinocytes we 
found an elastase inhibitor with an apparent molecular mass of about 18 kDa on SDS-
PAGE This inhibitor was otherwise indistinguishable from SKALP derived form psoriatic 
scales using biochemical and immunochemical entena3439 This led us to the hypothesis that 
the molecule synthesized in cultured human kerannocytes is a larger precursor molecule of 
the low molecular weight form found in psonatic scales We therefore purified SKALP from 
cultured human keratinocytes and determined its aminoterminal sequence SKALP purified 
from psonatic scales was used by others to obtain the complete amino acid sequence of a 6 
kDa fragment which was named elafin35 Companson of that sequence with the partial 
internal sequence we obtained from SKALP purified from cultured keratinocytes39 indicated 
that they represented the same molecule Sallenave and colleagues40 published a partial 
amino acid sequence of ESI purified from sputum, suggesting that ESI, SKALP, and elafin 
were the same molecule In retrospect we believe that the sputum-denved molecules 
described as bronchial secretion inhibitor (BSI-E) by Hochstrasser and colleagues41 and 
LMI-5000 (low molecular weight inhibitor, Mr = 5000) by Kramps and Klasen42 
represent the same inhibitor as ESI, and should hence be considered as the first 
descnption of what is now generally named SKALP or elafin 
13 
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A functional assay was used to measure the distribution of SKALP activity in the 
spreading psoriatic lesion. SKALP activity was found to be maximal in the center of the 
lesion and decreased towards the marginal zone. More than 4 mm outside the edge of 
the lesion SKALP activity was similar to that in normal skin43. As was mentioned 
previously, SKALP activity was not only demonstrated in psoriasis and after 
standardized injury but also in other scaling disorders33. In the erythrodermic form of 
autosomal recessive lamellar ichthyosis and in Netherton syndrome, elastase-inhibiting 
activity was significantly increased. Like psoriasis, these monogenic keratinization 
disorders also show a mixed inflammatory infiltrate. Non-inflammatory monogenic 
disorders of keratinization and atopic dermatitis, characterized by a mononuclear cell 
infiltrate without PMN, showed only a minor increase in elastase-inhibiting activity as 
compared to normal skin33. 
Initially, research focussed on the biochemical properties of SKALP. Extraction and 
purification of active SKALP involved boiling of homogenates of psoriatic scales and 
the use of buffers ranging from pH 3.0 to 11.035'39, indicating that SKALP is a very 
heat stable and pH stable molecule. Furthermore, SKALP was found to have an 
extremely high isoelectric point (pi > 10.5). The strong cationic nature of this molecule 
probably explains the significant deviation of the apparent molecular mass found on 
SDS-PAGE from the calculated molecular mass, since strongly cationic proteins 
migrate much slower on SDS-PAGE. 
SKALP was shown to be a specific inhibitor of human leukocyte elastase (HLE), 
porcine pancreatic elastase, and proteinase 3 but it does not inhibit the serine 
proteinases cathepsin G, trypsin, chymotrypsin and plasmin34,39,4446. Recently, 
chemically synthesized elafin (M
r
=6000) became available46. The inhibitory activities of 
chemically synthesized elafin are in the same range as found for the natural molecule 
yielding dissociation constants (K,) of 6xl0"10 M to 2x10" M for HLE, and 1x109M 
for porcine pancreatic elastase35'46,47. Elafin is also a potent inhibitor of proteinase 3, 
with a K, of 9.5x10"9 M44,45. The kinetics of inhibition of HLE by elafin were 
extensively mvestigated by Ying and Simon47. Their findings indicate that a single elafin 
molecule binds to a single site on the HLE molecule, blocking the reactive serine at the 
enzyme's catalytic center. Association of the enzyme with the inhibitor proceeds via a 
single bimolecular proces, with a second-order rate constant of З.бхІО6 М"У at pH 8.0 
and 25°C. Dissociation of the enzyme-inhibitor complex regenerates the inhibiting 
activity with at least 99.8%, showing that elafin is a fully reversible inhibitor. The K, 
of the enzyme-inhibitor complex was found to decrease from 6.7xlO"9 to 2.0xlO"10 M as 
the pH is increased from 5.4 to 9.0, revealing that the reaction rate is dependent on the 
concentration of the unprotonated form of a group with a pK
a
 of 6.8, which was 
assigned to the histidine in the enzyme's active site. 
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Sofar, research on SKALP mainly focussed on the biochemical and physiological 
aspects of this molecule At the start of the project described in this thesis no data were 
available on the molecular and cell biological aspects of SKALP 
Aim and outline of this thesis 
In 1991 two projects were initiated to study different aspects of SKALP One 
project, financially supported by the Faculty of Medicine of the University Hospital 
Nijmegen, was set up to study SKALP distribution and localization in VÌVO, and to 
investigate the cluneal applications of SKALP measurements m human tissues The 
second project, the work described m this thesis, was financially supported by the 
Netherlands Organization for Scientific Research (NWO) It was initiated to gain more 
insight m the molecular and cell biological aspects of SKALP Two mam aims were 
formulated 
• The molecular cloning and characterization of the human SKALP cDNA and the 
corresponding gene 
• Cell biological and molecular biological studies to mvestigate the regulation of 
SKALP gene expression m human keratinocytes 
Chapter 2 describes the cloning and characterization of the SKALP encoding cDNA 
and the purification of the SKALP protem from cultured human keratinocytes We 
showed that the newly synthesized SKALP molecule consists of three functionally 
different domains a signal peptide domam, a transglutaminase substrate domam and a 
proteinase inhibiting domam 
The human gene encoding SKALP was isolated mdependently by several groups In 
chapter 3 the isolation of our genomic DNA clones is described, and the collective data 
available about the human SKALP gene are reviewed In the 5'-upstream region of the 
SKALP gene we found a dinucleotide repeat polymorphism, which is described in this 
chapter Furthermore, we used our genomic clones to establish the chromosomal 
localization of the SKALP gene which is also described m this chapter 
In chapter 4 the expression of SKALP m dynamic models for keratinocyte growth 
and differentiation m vivo and m vitro is examined We found SKALP to be expressed 
аь a transient wave m the granular layer of the epidermis, following epidermal injury 
We used several keratinocyte culture systems to study SKALP expression m vitro The 




In chapter 5 we studied the expression of SKALP in several epidermal tumors that 
are characterized by abnormal differentiation. Using immunohistochemical staining, 
functional measurements of antiproteinase activity, and Western blotting of tumor 
extracts we found that SKALP is differentially expressed in these tumors, and that it 
can be used as a marker for disturbed squamous differentiation. 
In chapter 6 the preliminary characterization of a 5'-upstream region with promoter 
activity in the SKALP gene is described. We performed experiments to determine the 
transcription initiation site of the SKALP mRNA, and we used chimaeric expression 
vectors in transfection studies to identify regions with promoter activity. We show that 
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Purification and cDNA cloning of SKALP 
Abstract 
SKALP/Elafin is a proteinase inhibitor found in psoriatic epidermis as a short 
polypeptide of 6 kDa. Here we present evidence that this protein is synthesized as a 
larger precursor molecule with distinct biological features. Purification and NH2-
terminal sequencing of SKALP/elafin from cultured human keratinocytes and the 
cloning of its cDNA revealed the existence of a mature protein, which upon 
cleavage of a hydrophobic signal sequence of 22 amino acids has a calculated 
molecular mass of 9.9 kDa (95 amino acids). In addition to the known proteinase 
inhibitor domain, the mature protein contains a domain with 4 repeats which are 
homologous to putative transglutaminase substrate motifs. We were able to 
demonstrate on Western blots that immunoreactive SKALP is present in high 
molecular weight proteins extracted from psoriatic skin. This suggests that SKALP 
is covalently attached to epidermal proteins. In addition it was found that both the 
complete SKALP molecule and a synthetic peptide of the NH2-terminal portion of 
SKALP could be used as a transglutaminase substrate. We therefore speculate that 
SKALP/elafin, secreted by epidermal keratinocytes in inflamed skin, exists both as 
a free 6-kDa form and as an immobilized 9.9-kDa form covalently attached to the 
cornified envelopes by transglutaminase cross-linking. 
Introduction 
Elastase is a serine proteinase derived from polymorphonuclear leukocytes1. When 
secreted at sites of inflammation this enzyme can cause severe tissue damage, since it is 
active at neutral pH and can degrade a broad range of connective tissue components 
such as elastin2, proteoglycans3 and collagen4,5. The action of elastase, like that of many 
other proteinases, is controlled by proteinase inhibitors which are found in the 
extracellular fluids6. A crucial role for proteinases and their inhibitors has been 
suggested for several pathologic conditions, such as emphysema2'7, arthritis3·8, 
nephritis9, and certain skin diseases1011. 
Recently we have described a new, low molecular weight elastase inhibitor derived 
from psoriatic skin1213 termed SKALP (skin-derived antileukoproteinase). We 
demonstrated that this inhibitor can be found in the epidermis of several inflammatory 
skin diseases, but not in normal human epidermis. SKALP, also termed elafin by 
Wiedow et alu, was found both in the epidermis and in the urine of psoriatic patients15. 
Immunohistochemical studies showed that SKALP/elafin is found in the suprabasal 
differentiated keratinocytes of psoriatic epidermis16. 
23 
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In previous studies1213 we have shown that cultured human keratinocytes contain an 
elastase inhibitor with an apparent molecular mass of 18 kDa on SDS-PAGE, which is 
otherwise indistinguishable from SKALP/elafin derived from psoriatic epidermis usmg 
biochemical and immunochemical entena Here we desenbe the punfication, Non-
terminal sequencmg, and cDNA sequence analysis of this elastase inhibitor from 
cultured keratinocytes We conclude that this protein with a molecular mass of 9 9 kDa 
represents the precursor molecule of the 6-kDa form of SKALP/elafin found in 
psoriatic epidermis The NH2-terminal part of this precursor was also shown to contain 
a domain with putative transglutaminase substrate motifs Here we present evidence 
that transglutaminase-mediated cross-linking of SKALP can occur in human epidermis 
m vitro and m VÌVO 
Experimental procedures 
Keratinocyte culture and extraction 
Human epidermal keratinocytes were cultured according to the Rheinwald-Green 
system17 as previously desenbed18 Cells were grown to confluence and lysed in 20 ml 
0 025 mM tnethylamine per 100-ml tissue culture flask, containing approximately 20 χ 
IO6 cells Cell extracts were prepared by somcation on ice followed by centnfugation 
for 1 h at 40,000 χ g The supernatant was concentrated by vacuum centnfugation in a 
Speed-Vac concentrator (AS 160, Savant) The sample was dialyzed against distilled 
water, again centnfuged, and used for chromatography Usmg this procedure, 100-200 
ng of SKALP was obtained per 106 cells, assuming that all antielastase activity 
measured m the crude extract represents SKALP with a molecular mass of 9 9 kDa 
Biopsies 
Human skin biopsies (0 3 mm thickness) from healthy volunteers and psoriatic 
patients were taken with a keratotome as previously desenbed12 and used for 
keratinocyte cultures and RNA extraction 
Purification of SKALP 
Extracts from cultured keratinocytes were either directly used for reversed-phase 
chromatography or first punfied on a РВЕ 118 chromatofocusing column as desenbed 
before13 Samples were chromatographed on a mRPC C2/C18 PC 3 2/3 reversed-phase 
column usmg the SMART chromatography system (Pharmacia LKB Biotechnology 
INC ) at a flow of 240 ml per mm The gradient was 10 mm of 100% buffer A (0 1% 
tnfluoroacetic acid m distilled water), then 100% buffer A to 70% buffer В (0 1% 
tnfluoroacetic acid in acetonitnl) m 30 min (linear gradient) followed by a 5-min 
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gradient to 100% buffer В UV absorption was continuously recorded at 215 nm The 
anti-elastase activity of all fractions was measured fluonmetncally using a synthetic 
substrate as described before13, and active fractions of several runs were pooled and 
rechromatographed using the same conditions The fraction containing peak activity 
was freeze-dned, dissolved m phosphate-buffered saline, and subjected to gel 
permeation chromatography on a Superdex 75 PC 3 2/30 column (Pharmacia) using the 
SMART chromatography system The column was equilibrated with phosphate-
buffered saline, and a flow rate of 80 ml per nun was applied The column was 
calibrated with Blue dextran (void volume), ovalbumin (43 kDa), cytochrome с (12 
kDa), and L-dopa (total volume) as molecular mass markers (Sigma) Fractions were 
collected and antielastase activity was found m the major peak eluting from the column 
This material was analyzed (Eurosequence Ine , Groningen, The Netherlands) on a gas-
phase sequenator (Model 477A) and an on-line HPLC (Model 120A), from Applied 
Biosystems The material was not alkylated or otherwise modified prior to sequencing 
Synthesis of a specific cDNA hybridization probe 
Total RNA was isolated from psoriatic epidermis by the single-step guanidinium 
thiocyanate method of Chomczynski and Sacchi19 First strand cDNA was generated 
from total RNA with Moloney murine leukemia virus RNase H- reverse transcriptase 
(GIBCO-BRL Life Technologies) under conditions as suggested by the supplier, using 
excess ohgo(dT) primers Part of the total reverse transcriptase (RT) reaction was used 
for mixed ohgonucleotide-pnmed amplification of cDNA20 to generate a SKALP-speci-
fic hybridization probe Based on amino acid sequence data of elafin14 degenerate PCR-
pnmers were synthesized on a Gene Assembler Plus (Pharmacia) As the sense primer 
the degenerate codons for amino acids 1 to 7 were taken The antisense pnmer 
represents ammo acids 40 to 46, and the internal antisense pnmer contains the possible 
sequences encoding ammo acids 33 to 39 in elafin (see also Fig 2) All primers 
contained an additional BamW site to facilitate subcloning of the amplified DNA 
PCR-reactions were earned out usmg a DNA thermal Cycler (Perlon Elmer/Cetus) m 
50-ml mixtures covered with mineral oil The following buffer conditions were used 
16 5 mM ammonium sulfate, 65 mM Tns-HCl, pH 8 8, 0 065 mM EDTA, 0 17 mg/ml 
bovme serum albumin, 10 mM b-mercaptoethanol, 3 mM magnesium chlonde, 0 2 mM 
of each dNTP and 500 ng of each pnmer After an initial boiling of 10 mm the 
temperature was lowered to 80°C, and 1 unit of Taq polymerase was added 
Amplification was for 30 cycles as follows 60 s at 94°C, 90 s at 42°C, 90 s at 72°C 
An additional 10 nun at 72°C was used for the last cycle To determine the specificity 
of the resulting PCR product, the DNA was punfied from agarose gel and used as a 
template m a second PCR reaction under the same conditions with the sense pnmer and 
the internal antisense pnmer To rescue the onginal amplified cDNA, punfied cDNA 
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was treated with Proteinase K21, digested with ВатШ, subcloned into the ßowHI-sites 
of a pGEM-4 vector (Promega) and sequenced using the dideoxy chain termination 
procedure22 
Library screening 
To determine the hybridization conditions for library screening with a 243-base pair 
PCR-generated cDNA, this cDNA was initially used as a probe for Southern blot 
analysis of human blood cell genomic DNA following standard procedures23 Based on 
the results of this analysis, a random pruned human keratinocyte cDNA library in the 
vector lgtl 1 (HLlllOb, Clonetech) was screened with replica filters (Hybond N+, 
Amersham Corp ) at 65°C m hybridization buffer (500 mM sodium, 250 mM 
phosphate, pH 7 2, 7% SDS, 1 mM EDTA) Washing of the filters was performed at 
65°C in wash buffer (250 mM sodium, 125 mM phosphate, 1% SDS, 1 mM EDTA) 
The probe was labeled with 32P by random priming following standard procedures23 
Hybridizing phage plaques were purified and 1DNA was isolated A SacVKpnl-msert 
from one positive 1 clone was subcloned into pGEM-4 and used for further analysis 
Based on the results of Southern blot analysis of this clone, usmg the 243-base pair 
PCR-generated cDNA as a probe, an 0 5-kilobase pair EcoRl fragment was subcloned 
into pGEM-4, and both strands were completely sequenced 
Computer analysis 
DNA sequence gel readmgs were recorded and edited usmg the IG-suite 5 35 
package (Intelhgenetics, Ine ) on a SUN computer Protein analysis was earned out 
usmg the CAMMSA software package on a VAX computer as provided by the Dutch 
CAOS/CAMM center 
Antisera 
Antisera were raised agamst the 6-kDa form of SKALP/elafin which lacks the 
transglutaminase substrate domain We used both recombinant elafin (a kind gift of Dr 
N Russell, ICI, United Kingdom) or SKALP purified from psoriatic scales13 Protein 
(50 mg) was cross-linked with glutaraldehyde, dialysed agamst distilled water and 
emulsified with Freund's complete adjuvant13 Rabbits were immunized 
intracutaneously m the back, followed by two subcutaneous boosters at week 2 and 4 
Preimmune serum was drawn before the experiments and immune serum was collected 
after 6 weeks Titers in enzyme-linked immunosorbent assay were 1/20000 On 
Western blots, dilutions between 1/100 and 1/1000 were used The antisera were 
negative with extracts of normal human skin and human plasma proteins Antisera 
raised agamst recombinant material and agamst purified protein from scales yielded 
identical staining patterns 
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SDS-PAGE and Western blotting 
Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electroforesis 
(SDS-PAGE) on a 16 % gel, using tricine as a trailing ion instead of Tris-glycine24, or 
on a 12% gel using the conventional SDS-PAGE25. Molecular mass markers used were: 
broad range prestained markers from Bio-rad (myosin (205 kDa), b-galactosidase (116 
kDa), bovine serum albumin (80 kDa), ovalbumin (49.5 kDa), carbonic anhydrase 
(32.5 kDa), soybean trypsin inhibitor (27.5 kDa), lysozyme (18.5 kDa), and aprotinin 
(6.5 kDa)), and 14C-methylated proteins from Amersham (myosin (200 kDa), 
phsophorylase b (92 kDa), bovine serum albumin (69 kDa), ovalbumin (46 kDa), 
carbonic anhydrase (30 kDa), and lysozyme (14.3 kDa)). Molecular masses according 
to the manufacturers. Gels were electroblotted on polyvinylidenedifluoride (PVDF) 
membranes (Millipore), and protein staining was performed with Amido Black 
according to standard procedures. Immunological detection of proteins was performed 
using the antisera described above, followed by biotinylated swine-anti-rabbit Ig and 
avidin-conjugated alkaline phosphatase using a colorimetrie detection system1 . 
Preimmune serum of the same rabbits was used as a control. 
Preparation of a biotinylated peptide 
A peptide comprising amino acids 23 to 36 of SKALP (see also Fig. 2), containing a 
glutamine which is part of a GQDXVK motif, putatively involved in cross-linking, was 
synthesized (Eurosequence Ine, Groningen, The Netherlands). The peptide (250 mg) 
was biotinylated with 500 mg of NHS-LC-biotin (Pierce) for 2 h at 37°C in 300 ml of 
0 1 M Na2C03, pH 8.0. The reaction was stopped by the addition of 20 ml of 1 M Tris, 
pH 8.026. 
Cross-linking of the biotinylated peptide to stratum corneum proteins by 
endogenous and exogenous tranglutaminase 
Scales from a psoriatic patient (1 gram) were homogenized in 20 ml of phosphate 
buffered saline and centrifuged for 30 min at 40,000 χ g. The supernatant (2 mg of 
protein per ml) was sterilized through a 0.2-mm filter and stored at -20°C until further 
use For cross-linking experiments 10 ml of scale extract was used with 8 ml of 
biotinylated peptide solution26; either 0.01 unit of guinea pig liver transglutaminase 
(Sigma) or water (to measure the endogenous transglutaminase activity of the scale 
extract) was added. The reaction was initiated by the addition of СаСЬ at a 
concentration of 8.7 mM, in a final reaction volume of 20 ml. A reaction mixture 
containing 50 mM of EDTA was used as a control. After 16 h at 37°C the reaction 
mixtures were diluted with SDS-sample buffer (containing dithiothreitol) and boiled for 
2 min. Samples were subjected to SDS-PAGE (12% gel) and blotted onto PVDF 
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membrane Biotinylated proteins were detected with the Western Light kit (Tropix) 
according to the manufacturer's instructions This assay uses avidin-conjugated alkaline 
phosphatase and cherrulummescence of a sensitive alkaline phosphatase substrate 
Positive bands were printed on x-ray film 
Labeling of purified SKALP with [uC]methylamine; detection of uC-labeled protein 
SKALP purified from cultured keratinocytes as described above, was assayed to act 
as an amine acceptor using [14C]-methylamine as a probe27 SKALP (1 mg) was 
dissolved in 50 mM Tns, 100 mM NaCl, pH 7 5, containing 20% glycerol, 2 mM 
leupeptin, 1 mM phenylmethanesulfonylfluonde, 8 7 mM CaCl2, 0 01 umt guinea pig 
liver transglutaminase, and 1 MBq of [14C]methylamine (specific activity, 2 04 GBq per 
mmol) in a final volume of 25 ml After 2 h at 37°C the reaction was terminated by the 
addition of EDTA (20 mM final concentration) From this mixture 250 ng of SKALP 
was run on SDS-PAGE (16% gel) and blotted onto PVDF membrane as described 
above 14C-Labeled proteins (Amersham) were used as molecular mass markers The 
dried blot was used for autoradiography on x-ray film, with two intensifying screens, 
for 62 h 
Results 
Purification and NHr-terminal sequencing of SKALP 
Reversed-phase chromatography of soluble proteins extracted from cultured 
keratinocytes yielded one peak of antielastase activity as shown in Fig la Pooled 
fractions were, after rechromatography, finally purified on a Superdex 75 gel 
permeation column which gave a peak of antielastase activity coinciding with the major 
peak recorded at 215 nm (Fig lb) A Kav of 0 28 corresponding with an apparent 
molecular mass of 22 kDa was calculated NH2-terminal gas-phase sequencing of this 
material identified 26 amino acids (see Fig 2) of which the 7 COOH-terminal amino 
acids overlap with the NH2-terminal sequence of the 76-arruno acid form of elafin 
purified from psoriatic scales28 In Fig 2 the amino acid sequence of SKALP from 
cultured keratinocytes is compared with the known sequence data of elafin from 
psoriatic scales 
cDNA probe synthesis, library screening, and sequence analysis 
In order to verify and extend the protein sequence data we cloned and sequenced the 
SKALP-encoding cDNA Amplification of cDNA reverse-transcribed from psoriatic 
epidermis total RNA with the sense and antisense primer (Fig 2) resulted in 2 distinct 
cDNAs The largest cDNA of about 250 base pairs was used for a second PCR 
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reaction with the sense primer and the internal antisense primer (Fig. 2). This resulted 
in a shorter PCR product of about 230 base pairs. The 250-base pair product from the 
initial PCR reaction was subsequently subcloned into the BamHl site of a pGEM-4 
vector. One subclone, pGSKAl, containing the desired insert was characterized by 
DNA sequence analysis. The predicted amino acid sequence of the insert of clone 





Fig. 1. a, reversed-phase chromatography (mRPC C2/C18) of soluble proteins from cultured 
keratinocytes. Solid line, absorbance at 215 nm. Bars, antielastase activity expressed as units per 
fraction. 1 unit is the amount of inhibitor that gives 50% inhibition of 1 nmol of human leukocyte 
elastase13. b, gel permeation chromatography (Superdex 75) of partially purified SKALP obtained by 
reversed-phase chromatography. Solid line, absorbance at 215 nm. One fraction per minute was 
collected. Bars, antielastase activity in units per fraction. The material from fraction 16 was used for 
NH2-terminal sequencing. Vo, void volume; Ova, ovalbumin (43 kDa); Cyt-c, cytochrome с (12 kDa); 




Met Arg Ala Ser Ser Phe Leu Ile Val Val Val Phe Leu Ile Ala 015 
ATG AGG GCC AGC AGC TTC TTG АТС GTG GTG GTG TTC CTC АТС GCT 047 
i 
Gly Thr Leu Val Leu Glu Ala Ala Val Thr Gly Val Pro Val Lys 030 
GGG ACG CTG GTT СТА GAG GCA GCT GTC ACG GGA GTT CCT GTT AAA 092 
Gly Gin Asp Thr Val Lys Gly Arg Val Pro Phe Asn Gly Gin Asp 045 
GGT CAA GAC ACT GTC AAA GGC CGT GTT CCA TTC AAT GGA CAA GAT 137 
Pro Val Lys Gly Gin Val Ser Val Lys Gly Gin Asp Lys Val Lys 060 
CCC GTT AAA GGA CAA GTT TCA GTT AAA GGT CAA GAT AAA GTC AAA 182 
Ala Gin Glu Pro Val Lys Gly Pro Val Ser Thr Lys Pro Gly Ser 075 
GCG CAA GAG CCA GTC AAA GGT CCA GTC TCC ACT AAG CCT GGC TCC 227 
Cys Pro Ile Ile Leu Ile Arg Cys Ala Met Leu Asn Pro Pro Asn 090 
TGC CCC ATT АТС TTG АТС CGG TGC GCC ATG TTG AAT CCC CCT AAC 272 
Arg Cys Leu Lys Asp Thr Asp Cys Pro Gly Ile Lys Lys Cys Cys 105 
CGC TGC TTG AAA GAT ACT GAC TGC CCA GGA АТС AAG AAG TGC TGT 317 
Glu Gly Ser Cys Gly Met Ala Cys Phe Val Pro Gin END 117 
GAA GGC TCT TGC GGG ATG GCC TGT TTC GTT CCC CAG TGA GAGGGAG 363 
CCGGTCCTTGCTGCACCTGTGCCGTCCCCAGAGCTACAGGCCCCATCTGGTCCTAAGTC 422 
CCTGCTGCCCTTCCCCTTCCCACACTGTCCATTCTTCCTCCCATTCAGGATGCCCA-3' 478 
Fig. 2 Nucleotide sequence and amino acid sequence of preSKALP. The first 18 base pairs of the 
cDNA are not indicated in this figure (see "Results"). The deduced amino acid sequence reveals a 
protein of 117 ammo acids. The numbenng of the amino acids starts with the methionine. The cleavage 
site for the putative signal sequence (U) is indicated Ammo acids 23 to 48 and amino acids 85 to 100 
were confirmed by NH2-terminal gas-phase sequencmg of SKALP from cultured human keratinocytes 
(see "Results") and from psoriatic scales13, respectively Amino acids 61 to 117 and amino acids 42 to 
60 (underlined) are identical to, respectively, the amino acid sequence of elafm'" and an additional NHj-
terminal ammo acid sequence of elafin28 The sites to which the PCR primers were directed are double 
underlined. 
Subsequent screening of a human keratinocyte cDNA library (lxlO5 clones) with 
pGSKAl as a probe yielded three positive clones with larger inserts. After plaque 
purification and rescreening, the largest, clone FlAc53, was selected for further 
analysis. An £coRI-fragment which strongly hybridized with the cDNA probe, was 
subsequently subcloned into pGEM-4. Sequence analysis of the resulting subclone, 
designated pGESKA, revealed an insert comprising 496 base pairs, including an open 
reading frame coding for a 117-amino acid protein (Fig. 2) with a calculated molecular 
mass of 12.3 kDa, an isoelectric point of 8.84 and a putative signal sequence of 22 
amino acids29. The first 18 base pairs of the 5'-untranslated region are scrambled with a 
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28 S rRNA gene fragment. The З'-untranslated region comprises 122 nucleotides and 
does not contain a poly(A)-tail nor a polyadenylation signal since a random primed 
cDNA library was used. 
Cross-linking of SKALP 
The NH2-terminal part of the 9.9-kDa SKALP-protein (amino acid 23 to 68 in Fig. 
2) from cultured keratinocytes contains four repeats which match remarkably well with 
a consensus sequence for transglutaminase cross-linking, first described in seminal 
vesicle protein I from guinea pig30'31. Covalent clotting of this protein is catalyzed by a 
transglutaminase, involving the formation of g-glutamyl-e-lysine cross-links. Three 
residues in these repeats, 2 lysines and 1 glutamine, are thought to participate in the 
cross-links. Fig. 3 shows the repeats in SKALP as compared to the supposed consensus 
sequence for transglutaminase-catalyzed cross-linking. 
C o n s e n s u s : GQDxVKxxxxxK 
R e p e a t a 
R e p e a t b 
R e p e a t с 
R e p e a t d 
31GQDTVKGRVPFN42 
4 3GQDPVKGQVS VK5 4 
4 9GQVSVKGQDKVK6 0 
55GQDKVKAQE Ρ VK 6 6 
Fig 3 Comparison of four repeats in the putative transglutaminase substrate domain with the supposed 
consensus sequence for transg 
Numbering is according to Fig 2 
lutaminase cross-linking30'31 Identical amino acids are marked. 
To investigate whether SKALP can act as a transglutaminase substrate, three 
strategies were followed. 
First, we extracted proteins from psoriatic scales directly in SDS-sample buffer and 
ran them on SDS-PAGE (16% gel). The proteins were blotted on PVDF membrane and 
stained with an antiserum against the low molecular weight (6 kDa) form of SKALP. 
As shown m Fig. 4a (lane 4) several forms of SKALP appear to be present in scale 
extract (including the 9.9- and the 6-kDa forms). It should be noted that the molecular 
mass determination of SKALP is not reliable on these gels (as indicated by the marker 
proteins) due to the cationic nature of the molecule as described before1314 In addition 
to the expected SKALP forms, in lane 4, positive bands in the higher molecular weight 
range are visible, suggesting that SKALP is covalently attached to other proteins. No 
positive reaction of the antisera with high molecular weight proteins in extracts of 
normal skin was found. For comparison partially purified SKALP/elafin from psoriatic 
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scales (lane 1), purified SKALP from cultured cells (lane 3) and recombinant 
elafin/SKALP (lane 2) were stained on the same blot as shown in Fig. 4a. 
116.5 — 
80 — I 49.5— 32.5— 
27.5 — 
18.5— ^ _ 
в 1 2 3 4 
Fig. 4. A, immunoblots of SKALP preparations and scale extracts with anti-SKALP serum. Lane 2, 
recombinant elafin/SKALP (6 kDa); lane 3, purified SKALP from cultured keratinocytes (9.9 kDa); lane 
1, partially purified SKALP/elafin from psoriatic scales, containing multiple forms of SKALP/elafin, 
including the 6- and 9.9-kDa forms; lane 4, total scale extract showing additional high molecular weight 
proteins, suggesting cross-linking of SKALP to proteins of the stratum corneum. B, autoradiograph from 
a Western blot of SDS-PAGE demonstrating linkage of a biotinylated peptide to stratum comeum 
proteins by transglutaminase. Lane 1, scale extract without biotinylated peptide; lane 2, scale extract 
with biotinylated peptide; lane 3, scale extract with biotinylated peptide and exogenous 
transglutaminase; lane 4, scale extract with biotinylated peptide in the presence of EDTA. C, 
autoradiograph from a Western blot of SDS-PAGE showing purified SKALP (9.9-kDa form) as an 
amine acceptor with [14C]-methylamine as a probe (lane 2). Radiolabeled markers are shown in lane 1. 
Second, we used a biotinylated synthetic peptide comprising amino acids 23 to 36 of 
SKALP, as a substrate for transglutaminase. The peptide was derived from the NH2-
terminal domain and contained a glutamine of a putative transglutaminase substrate 
motif as a potential amine acceptor. The biotinylated peptide was added to extracts of 
psoriatic scales, with or without exogenous transglutaminase. The presence of an excess 
EDTA was used a control for the Ca2+-dependent reaction. Fig. Ab shows that the 
biotinylated peptide is cross-linked to many skin proteins in the absence of exogenous 
transglutaminase (lane 2), presumably by the action of endogenous epidermal 
transglutaminase which is known to be present in psoriatic scales32. Addition of liver 
transglutaminase (lane 3) clearly increases the amount of labeled proteins. EDTA 
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almost completely blocks the formation of biotinylated skin proteins (lane 4), 
presumably by inhibiting transglutaminase activity 
Third, highly purified SKALP from cultured keratuiocytes (9 9-kDa form) was used 
as a substrate for guinea pig liver transglutaminase, using [14C]methylamme as an acyl-
acceptor probe Fig 4c shows that SKALP can indeed act as a substrate m this 
reaction 
Discussion 
From comparison of the predicted ammo acid sequence of our cloned cDNA with the 
known ammo acid sequence of elafin and our protem sequence data of SKALP (Fig 2) 
we conclude that clone pGESKA encodes the complete preSKALP protein 
When this manuscript was in preparation, the genomic organization and complete 
nucleotide sequence of the human elafin gene were reported33 Comparison of our 
cDNA with the predicted exon sequences shows 100% homology, confirming that 
SKALP and elafin indeed are identical proteins 
Three domains in preSKALP 
A signal peptide cleavage site m preSKALP is predicted29 between ammo acid 
residues 22 and 23 Based on the genomic DNA sequence33 it was speculated that the 
signal peptide spans a region of 25 ammo acids However, this was not supported by 
sequence data at the protem level Our results from the NH2-terminal gas-phase 
sequencing of SKALP purified from cultured keratuiocytes clearly show that the protem 
starts at ammo acid 23 from the cDNA-deduced ammo acid sequence (Fig 2) We 
therefore conclude that this protem indeed is the preSKALP polypeptide, and that the 
site of cleavage for the signal peptide as we predict it must be correct 
The presence of a putative signal sequence suggests that translation of SKALP-
codmg mRNA takes place at the rough endoplasmic reticulum34 It is not yet clear 
through which intracellular routes the protein is finally secreted, and this is currently 
under investigation 
The COOH-ternunal part of SKALP contains 8 cysteme residues which are 
probably involved m disulfide bonds Small proteins showing this characteristic have 
been called "four-disulfide core" proteins35 Several proteins have been shown to belong 
to this group, like whey acidic protein36, the sodium potassium ATPase inhibitors 1, 2 
and 337 and antileukoprotease/secretory leukocyte protease inhibitor (ALP/SLPI)38 39 
The COOH-ternunal part of ALP/SLPI shows 40% homology with the COOH-temunal 
part of SKALP (amino acid 68 to 117 m Fig 2) and especially the positions of the 
cysteine residues are highly conserved The NH2-terminal parts of SKALP and 
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ALP/SLPI show no significant homology Based on the homology between the COOH-
temunal parts of SKALP and ALP/SLPI, we denote the domain spanning amino acid 
68 to 117 (Fig 2) of SKALP as being the proteinase inhibiting domain 
The NH2-terminal part of SKALP was shown to contain four repeats, highly 
homologous to a consensus sequence for transglutaminase cross-linking, as we already 
mentioned (see "Results") Based on this striking homology, we surmised that this 
region can act as a putative substrate domam for epidermal transglutaminase Our 
transglutaminase experiments clearly show that SKALP can mdeed become cross-
linked by transglutaminase to proteins extracted from psoriatic scales It is therefore 
tempting to speculate that SKALP can exist as an immobilized 9 9-kDa protem, 
covalently attached to the cornified envelopes by transglutaminase cross-linking 
Currently, experiments with the 9 9-kDa form of SKALP as a product of recombinant 
DNA technology, m combination with site-directed mutagenesis, are m progress m 
order to determine the exact sites used for cross-linking 
Immunohistochemical staining of psoriatic epidermis suggests that at least part of 
the SKALP present m the epidermis is mdeed closely associated to the cornified 
envelopes16 However, extraction and purification of SKALP/elafin from psoriatic 
scales predominantly yields a low molecular weight form1314 We therefore speculate 
that m psoriatic lesions a mechanism exists to cleave the protemase inhibiting domam 
from the putative transglutaminase domam Cross-linking to the cornified envelopes 
might be a prerequisite for this mechanism smce, m cultured keratinocytes, where 
cornified envelopes are not present, we mainly find the complete 9 9-kDa protem 
Further studies on in vitro and m vivo differentiation of keratinocytes should give us a 
more detailed msight into the pathways of SKALP processmg 
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Abstract 
In the previous chapter we described the isolation and characterization of a 
cDNA clone encoding the complete precursor of the human proteinase inhibitor 
skin-derived antileukoproteinase (SKALP). We used this cDNA clone as probe to 
identify and isolate a genomic DNA fragment containing the human SKALP gene. 
The same gene was isolated independently by others. Here we review the collective 
data available and, in addition, describe a diallelic dinucleotide repeat 
polymorphism in the 5'-upstream region of the SKALP gene. Furthermore, we 
report the localization of the human gene within chromosome region 20ql2-ql3. 
This gene has been given the approved symbol PI3 by the Human Gene Mapping 
(HGM) nomenclature committee. 
Introduction 
Previously, we have described a new elastase inhibitor derived from psoriatic 
epidermis1,2 termed SKALP (skin-derived antileukoproteinase), described by others as 
elafin3 and elastase-specific inhibitor4. It was shown that SKALP is a potent inhibitor of 
the enzymes elastase and proteinase-3, derived from PMNs (polymorphonuclear 
leukocytes). These enzymes have been implicated in several pathologic conditions, like 
emphysema5, arthritis6, nephritis7, and certain skin diseases8. SKALP expression is 
absent in normal human epidermis but is found to be induced during inflammatory 
responses and epidermal injury1'9. We therefore assume that it plays a role in the control 
of cutaneous inflammation. 
In the previous chapter we described the purification and cDNA sequence of 
SKALP from cultured human keratinocytes10. It was found that in cultured 
keratinocytes SKALP is synthesized as a preprotein with a signal peptide of 22 amino 
acids. Cleavage of this signal peptide results in a mature protein of 95 amino acids (9.9 
kDa) which contains a domain with four aminoterminal transglutaminase substrate 
motifs m addition to the proteinase inhibitor domain. It was shown that SKALP can 
indeed act as a substrate for transglutaminase as SKALP can become cross-linked by 
transglutaminase to high molecular weight proteins extracted from psoriatic scales. 
In order to gain insight in the genomic organization of the SKALP gene and the 
regulation of SKALP gene expression, we have isolated the human gene encoding 
SKALP. While this work was in progress the same gene was isolated independently by 
others"12 Here we describe the complete nucleotide sequence and the organization of 
the human SKALP gene, reviewing the collective data available. Also, the identification 
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of a useful genetic marker in the 5'-upstream region of the gene is reported. To 
establish the chromosomal localization of the human SKALP gene, we used our clones 
for Southern blot analysis of a panel of human-rodent hybrid cell lines and for non­
radioactive in situ hybridization on R-banded human lymphocyte-derived chromosome 
spreads. 
Experimental procedures 
Isolation of the SKALP gene 
We used a 445 bp Xba\ fragment from our SKALP cDNA clone pGESKA10 to 
screen a human genomic DNA library in the phage vector XEMBL-3 (kindly provided 
by Dr Grosveld, Erasmus University, Rotterdam, The Netherlands). The probe was 
labeled with 3 2P using standard procedures13. Hybridization of the filters was carried 
out at 65°C in hybridization buffer (500 mM sodium chloride, 250 mM phosphate pH 
7.2, 7% SDS, 1 mM EDTA). Washing of the filters was performed at the same 
temperature in wash buffer (250 mM sodium chloride, 125 mM phosphate pH 7.2, 1% 
SDS, 1 mM EDTA). Hybridizing phage plaques were selected for rescreening. After 
two subsequent rounds of rescreening, XDNA was isolated. A 9 kb ЯшсЛІІ-fragment 
showing hybridization on Southern blots with the 445 bp SKALP cDNA probe was 
subcloned in a pBluescript vector (Stratagene). The resulting clone, designated pSKAG, 
was used for further analysis. Several subclones were derived from clone pSKAG using 
standard cloning techniques13 and sequenced using the dideoxy chain termination 
method14. DNA sequence gel readings were edited and analyzed using the Fragment 
Assembly System package (Genetics Computer Group, Inc.) on a UNDÍ computer 
(Silicon Graphics Systems). Assignment of the intron-exon boundaries was confirmed 
with the NetGene neural network prediction of splice sites15. Computer services were 
provided by the Dutch CAOS/CAMM Center. 
Analysis of a dinucleotide repeat in the S'-upstream region 
Sequence analysis of the SKALP gene revealed the presence of a (CA) repeat in the 
5'-upstream promoter region, from position 105 to 153 (Fig. 1). Primers flanking this 
repeat were designed in order to amplify by PCR a fragment of 156 bp according to the 
reported sequence (pos. 23 to 178, Fig. 1). The primers used were, forward: 5'-
ACCTTTTCCAGAAGAAGGAACC-3' and reverse: 5'-
CCTGACCCCTGACCACAG-3'. PCR reactions were carried out on a DNA Thermal 
Cycler (Perkin Elmer) in 50 μΐ mixtures covered with mineral oil. Each PCR reaction 
contained 200 ng genomic DNA, 125 ng of each primer, 0.2 mM of each dNTP and 1 
U Taq DNA polymerase (Gibco BRL, Breda, The Netherlands) in a reaction buffer 
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containing 20 mM Tns-HCl and 50 mM KCl with a pH of 8 4 For visualization of the 
PCR products by autoradiography, approximately 25 kBq of 32PdCTP (specific 
activity, 110 Tbq/mmol) was added to each PCR reaction After an initial denaturation 
step at 95°C for 5 min, reactions were processed through 35 cycles of 94°C for 1 nun, 
58°C for 1 mm, and 72°C for 2 mm, followed by a final elongation step at 72°C for 10 
nun The sizes of the alleles were determined on 8% denaturing Polyacrylamide gels13 
by comparison with a sequencing ladder which was generated using the dideoxy chain 
termination method14 The allele frequency was estimated from 96 chromosomes of 
unrelated individuals Mendehan segregation was tested m one three-generation family 
DNA was isolated from blood samples according to standard procedures13 
Preparation of cell hybrid DNA and Southern blot analysis 
For chromosomal localization studies, a panel of well characterized human-rodent 
somatic cell hybrids was used16 These hybrid cell lmes were isolated after fusion of 
human leukocytes from various donors, with hypoxanthine phosphonbosyl transferase-
or thymidine kinase-deficient rodent (hamster) cell lmes Cells were grown in FIO or 
RPMI-1640 medium, supplemented with 2 mM glutamine, antibiotics, and 10% fetal 
calf serum To analyze the chromosomal constitution of the hybrid cell lmes, air-dned 
spreads were made as previously described16 At least 16 metaphases of each cell Ime 
were examined usmg R-banding after heat denaturation Genomic DNA was isolated, 
separated by agarose gel electrophoresis and blotted usmg standard procedures13 
Southern blots were hybridized with the 3 2P labeled 445 bp Xbal SKALP cDNA 
fragment as probe Chromosome analysis and DNA extraction were always earned out 
on the same batches of cells 
Fluorescence in situ hybridization (FISH) 
For regional localization of the SKALP gene, non-radioactive m situ hybridization 
was performed on R-banded normal human lymphocyte chromosome spreads17 usmg 
clone pSKAG, containing the complete SKALP gene, as a probe DNA was labeled 
with biotin-14-dATP (Life Technologies) by rack translation and purified 100 ng of the 
labeled DNA was ethanol precipitated, together with 5 0 ug of sonicated herring sperm 
DNA and 5 mg Cot-1 DNA (Life Technologies) The precipitated DNA was dissolved 
in 10 μΐ of hybridization mixture containing 2XSSC, 10% dextrane sulphate, 1% 
Tween-20, and 50% formamide Prior to hybridization, the probe DNA was denatured 
at 80°C for 10 mm, followed by an incubation for 20 mm at 37°C to allow preannealing 
of highly reiterated sequences The preannealed probe mixture was finally added to 
heat-denatured chromosome spreads and enclosed under a 18X18 mm cover slip 
Hybridization was subsequently earned out overnight m a moist chamber at 37°C 
After posthybndization washings and blockmg with nonfat dry milk powder (Protifar, 
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Nutricia), ïmmunocytochemical detection of the hybridizing probe DNA was 
accomplished by means of subsequent incubations with fluorescein lsothiocyanate 
(FITC), conjugated to avidin-D and biotinylated goat anti-avidin antibody (Vector 
Laboratories), including one extra round of FITC amplification19 R-bandmg was 
obtained using Hoechst 33258 (0 1 ug/ml) for 15 mm, UV light radiation (364 nm for 
20 mm) and denaturation m Earl's solution (pH 6 5 at 87°C for 30-120 s) as 
described17 After a second round of signal amplification, chromosome spreads were 
finally mounted in anti-fade solution, supplemented with propidium iodide (1 ug/ml) 
(Sigma) for counterstaining Chromosomes were viewed under a Zeiss Axiophot 
epifluorescence microscope, equipped with appropriate filters for visualization of FITC 
and propidium iodide fluorescence Digital images were captured usmg a high 
performance CH250/A cooled CCD-camera (Photometries Ltd, USA) coupled to a 
Macmtosh Ilei computer and displayed m green-red pseudocolors Photographs were 
taken from the computer screen usmg a Kodak EPP 100 color slide film 
Results 
The human SKALPgene 
Screening of a human genomic DNA library m the vector XEMBL-3 resulted in 3 
positive plaques One plaque, showing the strongest hybridization signal, was selected 
for further analysis A 9 kb Hmdlll fragment from this plaque, showmg hybridization 
with the pGESKA-denved Xba\ as a probe, was subsequently subcloned m pBluescnpt, 
resulting in clone pSKAG Sequence analysis of subclones derived from genomic DNA 
clone pSKAG resulted m a partial nucleotide sequence of the human SKALP gene The 
gene was completely sequenced by Saheki and collegues11 Their data comprise the 
nucleotides 765 to 2643 m Fig 1 These data were confirmed by Sallenave and 
collegues12 Comparison of our partial sequence data with the sequence of SKALP 
cDNA clone pGESKA10 and with the data of Saheki and collegues11 and Sallenave and 
collegues12 showed that our clone mdeed contains the SKALP gene In Fig 1 the 
collective data of Saheki and the sequence data from our work (nucleotide 1 to 1075) 
are presented, together with the deduced ammo acid sequence 
The human SKALP gene spans more than 2 6 kb, containing three exons and two 
introns The 573' GT/AG consensus nucleotides are found at all splice sites20 The first 
exon contains the 5'-noncoding region and the first 79 nucleotides of the codmg 
sequence, encoding the hydrophobic signal sequence as well as the first 4 amino acids 
of the mature protein The second exon encodes the rest of the protein and the first 
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nucleotide of the 3'-noncoding region. The rest of the З'-noncoding region, including the 
polyadenylation signal (pos. 2612), is completely encoded by the third exon. 
1 a a t t c c c t g g t t c a t a t a t a t c a c c t t t t c c a g a a g a a g g a a c c c c c g t t t t c c c c t t t c 60 






т я 120 
1Θ1 ttcatgattagcagtccccattagactcacaagttgatggttcaaagagacaacaattct 240 
241 tcacaagaaacagggtgctgttcaaagaagtggggaggcatgctggacacacacactgta 300 
301 gatgtccaatgtatacatgatacatgttttctactactttctgattattttctccctacc 360 
361 actgtgatttcaagggcatcatccctcttcagacctagaattccaccttccaattacttt 420 
421 cttgatgcatctgaaaggccgtctctgaaacagcaaagtgcaataattagtcattatgta 480 
4Θ1 ttcaaggcaaatttgtcttacagagttttttgcaggaccagggaagaaggaaggaaatgc 540 
541 ccagtttgatgctgggagtggtaaaatgataaagtagatctgggtggggtttgtagcacc 600 
601 agagcataatggagaaacaccttggttttgtaatcaagactggatctaccagtgacttgc 660 
661 tgaataaccttcggtgattcctttctcttcttgggtctcactgtatttcaaaacatgaag 720 
721 aattteattgtaatgttacetaataagtgagccagcacttctactctgtgagaaagtagg 780 
781 aaaactcttgggacaatcagagatgatgtgatgtaatgtccattagttcttcctgtgaat 840 
841 aatcctqaqqqaaaqcccccaqqtccctcccaqaatqqqqtqqatatttcccaatacagc 900 
901 taaqqaattatcccttataaataccacaqacccgcccctgqaqccAGGCCAAGCTGGACT 960 
961 GCATAAAGATTGGTArGGCCrTAGCTCrTAGCCAAflCACCTrCCrGACACCATGAGGGCC 1020 
M R A 
1021 AGCAGCTTCTTGATCGTGGTGGTGTTCCTCATCGCTGGGACGCTGGTTCTAGAGGCAGCT 10B0 
S S F L I V V V F L I A G T L V L E A A 
1081 GTCACGGGAGgtgagtgaacaggtgacctgctgggctgggttggactaaggggagaccct 1140 
V Τ G V 
1141 ctgggacaccctgggccaggacagggagcactactgaagcagtaggcagcactggagccc 1200 
1201 agatttcagctttctgttctttgccatcatattcagaaaaaataggactttggctggtgg 1260 
1261 actccacgtgctttccacctcagtgactgagatatcaggactgtttgtggaagtaatgtt 1320 
1321 ggtatgtggccttggcctcagatgtcaatacctgtgcagaatgtgcaataaaataatgaa 13Θ0 
13Θ1 ctccaggattttaaaccttgggtgtggacacagtcccccgtttctctgccccataaaagc 144 0 
14 41 actggagtaatgagtactctaaaaggaggttaagaaacaacaagccttcaggaatcatgt 1500 
1501 tgtttgaggacccccattttataaggagggaaccaaaaatgtagaaatgagtgagcaatt 1560 
1561 gccaaggtaattcccagagccaggatggggctcaagtctcctagtatgtggctcagggtt 1620 
1621 ctttcctactccaatgcacttcttaacaaatgacaatgtgtcctcttcactgctgggtgt 1680 
16Θ1 caccccagtctgaccactgctcctgagagacttggagtggaggaagggggaagaaacaaa 1740 
17 41 tactcaagggaactctggtcctgtagaccaccccaaaaaaggaagagccttccaagagtg 1800 
1Θ01 tagctcccagaggtgtacettecetactcaggccatggtttgaggatgctgcagtaagca I860 
1861 gtggatggacccagacccagaggaaagacatggcagctgaagcagaggcttactgggtat 1920 
1921 aaatgtgggctcgtttcttcttttaacagTTCCTGTTAAAGGTCAAGACACTGTCAAAGG 1980 
P V K G Q D T V K G 
1981 CCGTGTTCCATTCAATGGACAAGATCCCGTTAAAGGACAAGTTTCAGTTAAAGGTCAAGA 2040 
R V P F N G Q D P V K G Q V S V K G Q D 
2041 TAAAGTCAAAGCGCAAGAGCCAGTCAAAGGTCCAGTCTCCACTAAGCCTGGCTCCTGCCC 2100 
K V K A Q E P V K G P V S T K P G S C P 
2101 CATTATCTTGATCCGGTGCGCCATGTTGAATCCCCCTAACCGCTGCTTGAAAGATACTGA 2160 
I I L I R C A M L N P P N R C L K D T D 
2161 CTGCCCAGGAATCAAGAAGTGCTGTGAAGGCTCTTGCGGGATGGCCTGTTTCGTTCCCCA 2220 
C P G I K K C C E G S C G M A C F V P Q 
2221 GTGAGgtgagcactagetggagaacgaggagacccctgaagacacaaaagaaggctgage 22Θ0 
END 
2281 ggtggggaagcatcccaggttggtgggaggtaggttgtgggaggtgacagaaagactggg 2340 
2341 agagctgaggggtctgagaggctataaccagagtgcctagaaggatgatctgtcttcctc 24 00 
2401 actgcctctgagtgctttgatgtgctgactctcacctctgatactcttctcttccacagA 24 60 
2461 GGGAGCCGGTCCTTGCTGCACCTGTGCCGTCCCCAGAGCTACAGGCCCCATCTGGTCCTA 2520 
2521 AGTCCCTGCTGCCCTTCCCCTTCCCACACTGTCCATTCTTCCTCCCATTCAGGATGCCCA 2 5Θ0 
25B1 CGGCTGGAGCTGCCTCTCTCATCCACTTTCCAATAAAqaattccttctoctccacttqtt 2640 
2641 tct 
Fig 1. Nucleotide sequence of the human SKALP gene. The translation start site is underlined. Putative 
CAAT- and TATA-boxes and the polyadenylation signal are double underlined. Below the nucleotide 
sequence the translation product is shown. Exon sequences are represented in capitals. A small open 
reading frame in the S'-untranslated region is printed in italics. A dinucleotide repeat in the 5'-upstream 
region is printed in bold face 
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The organization of the SKALP gene and the resulting cDNA are shown in Fig. 2. 
The start codon for the SKALP precursor protein is found at position 1012 (Fig. 1). 
The sequence preceding the translational start site matches well with the consensus sequence 
for strong eukaryotic initiation of translation21. Two consensus sequences, a "CAAT box" 
and a "TATA box" are found at positions 892 and 918 respectively. A small open 
reading frame of 33 nucleotides is found just upstream of the used ATG, starting at 
position 975. 
Fig. 2. Schematic representation of the organization of the SKALP gene and the resulting mRNA. a: 
hydrophobic signal sequence encoding region (22 amino acids), b: transglutaminase substrate domain 
encoding region (45 amino acids), c: proteinase inhibiting domain encoding region (50 amino acids). 
A dinucleotide repeat polymorphism in the 5'-upstream region 
When we sequenced the human SKALP gene, we noted a dinucleotide repeat in the 
5'-upstream region of the gene (see Fig. 1). The form of the repeat is: 
TCT(CA)4A(CA)7CT(CA)i2CCC. PCR reactions on genomic DNA of 48 unrelated 
individuals showed this repeat to be polymorphic. In all individuals tested we found a 
156 bp PCR product, but in 13 cases an additional PCR product with a length of 160 
bp was found, resulting in a heterozygosity of 0.27. Mendelian inheritance was 
observed in one three-generation family. The estimated allele frequencies are shown in 
Table 1. 
Table 1. Estimated allele frequencies found for the dinucleotide repeat polymorphism in the human 
SKALP gene. 
Allele bp Frequency 
Al 160 0.135 
A2 156 0.865 
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Localization of the SKALP gene 
To analyze the chromosomal localization of the human SKALP gene, a 32P-labeled 
445 bp Xbal cDNA fragment from SKALP clone pGESKA10 was hybridized to a panel 
of 25 human-hamster hybrid cell lines, all containing a full complement of hamster 
chromosomes but various subsets of human chromosomes (Table 2). The probe showed 
hybridization to a 9 kb Hmdlll fragment in control human DNA. No cross-
hybridization to control hamster DNA was observed under the stringency conditions 
used. In all cell hybrids containing human chromosome 20 a positive 9 kb hybridizing 
SKALP signal was observed, indicating that the human gene may reside on this 
chromosome A positive signal was also obtained in two cell lines that were scored 
negative for chromosome 20 after cytogenetic analysis. This discordancy most probably 
results from chromosomal rearrangement after cell fusion which is a well known 
phenomenon. For all other human chromosomes the discordancy scores were invariably 
higher (see Table 2). In order to confirm and further refine the localization of the 
SKALP gene, non-radioactive in situ hybridization was carried out, using SKALP 
genomic DNA clone pSKAG as a probe, in conjunction with R-banding. In total 30 
metaphase spreads were scored. A positive hybridizing signal was observed in all of 
these metaphases on chromosome 20 only, usually on both homologs present. These 
results thus confirm the above localization using the somatic cell hybrid approach. 
Comparison of the, from DAPI staining converted, G-banding pattern of the 
corresponding chromosomes allowed us to definitely assign the SKALP (PI3) gene to 
the region 20ql2-ql3 (Fig. 3). 
Conclusions and discussion 
Comparison of the nucleotide sequence data obtained from our genomic clone 
pSKAG with the SKALP cDNA clone pGESKA10 leads to the conclusion that we have 
indeed cloned the human gene encoding the serine proteinase inhibitor SKALP. While 
this work was in progress, the same gene was isolated independently by several other 
groups. Saheki and colleagues screened a human genomic DNA library with a porcine 
sodium-potassium ATPase inhibitor (SPAI) cDNA probe under moderate stringency 
conditions". Due to the partial homology between SKALP and SPAI they were able to 
isolate the human SKALP gene. Their results were confirmed by Sallenave and 
colleagues, who previously showed SKALP to be synthesized by lung-derived cell 
lines42223 They cloned the human SKALP gene using a cDNA clone encoding the 57 
amino acids of elafin12. 
Interestingly, the 5'-noncoding region of the SKALP gene contains a small open 
reading frame consisting of 33 nucleotides. This is remarkable since translation of 
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eukaryotic mRNAs usually starts at the first AUG24. Whether this small open reading 
frame is translated and, if so, what the functional role of the resulting peptide might be, 
is not clear. Only 5-10% of vertebrate mRNAs have upstream AUG codons, many of 
Table 2 Discordancy analysis of human SKALP hybridizing fragments and human chromosomes in 25 
human/rodent somatic cell hybrids' 
Chromosome / SKALP (number of clones) 
Chromo- Percent 












































































































































 Concordant hybrids have retained the indicated chromosome and give a positive signal on Southern 
blots (+/+) or have lost that chromosome and are negative upon hybridization with the Xbal probe (-/-) 
Discordant hybrids either show hybridization with the Xbal probe and have lost a specific chromosome 
(-/+) or show no hybridization with this probe but have retained that chromosome (+/-) The percentage 
discordancy was calculated by devidmg the total number of discordant hybrids by the number of hybrids 
exammed(XlOO) 
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them being protooncogenes, growth-control genes and receptor genes . The role of 
these upstream AUG codons is not clear in higher eukaryotes, but in yeast it has been 
shown that upstream AUGs can repress the efficiency of translation initiation of the 
long downstream open reading frame, and thus play a role in the regulation of 
translation29"31. 
Fig. 3. Chromosomal FISH mapping of the human SKALP gene (PI3). Hybridization signals appear as 
double spots in the chromosome region 20ql2—>ql 3 (arrow). 
A dinucleotide repeat polymorphism was found in the 5'-upstream region of the 
SKALP gene. Of the 48 tested individuals, 27% was found to be heterozygous for the 
(CA)n repeat present in the SKALP gene promoter region. Although the heterozygosity 
found for this repeat is relatively low (0.27), it may be of value for future detection of 
genetically determined abnormalities. At present no skin disease has to our knowledge 
been mapped to chromosome 20. Interestingly, a cluster of other proteinase inhibitors, 
the cystatins, have been mapped to chromosome 2032. Although no structural homology 
was found between SKALP and the cystatins, they share a curious functional property 
since they can all act as transglutaminase substrates. Both SKALP and cystatin a were 
found to be cross-linked to cornified envelope proteins10'3 . Future studies might shed 
further light on the possible functions of SKALP in inflammation control and protection 
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SKALP in epidermal keratinocytes 
Abstract 
Skin-derived antileukoproteinase (SKALP), otherwise known as elafin, is a 
recently discovered epidermal proteinase inhibitor with specificity for 
polymorphonuclear leukocyte (PMN)-derived elastase and proteinase-3; in 
addition to the proteinase-inhibiting domain, SKALP contains several 
transglutaminase substrate motifs. SKALP is virtually absent in normal human 
epidermis but is found in a number of inflammatory skin diseases, including 
psoriasis. Here we report the induction and processing of SKALP in vivo and in 
vitro. SKALP-expression in vivo could be demonstrated following injury in normal 
human epidermis, using histology, Western blotting, Northern blotting and a 
functional assay. In vitro, SKALP expression was studied in conventional 
submerged keratinocyte culture systems and in keratinocytes cultured in an air-
liquid interface model. Induction of SKALP-activity in epidermis could be 
measured as early as 16 h after skin injury; immunohistological examination 
showed that SKALP expression was confined to the outer layers of the stratum 
spinosum and the stratum granulosum. Northern blot analysis revealed a 0.8 kb 
transcript, both in vivo (psoriatic skin, injured skin) and in vitro (cultured 
keratinocytes). Western blot analysis showed that the major SKALP form in vivo 
was a low molecular mass fragment, containing the antiproteinase domain. In all 
cultures that were positive for SKALP, larger (8-10 kDa) forms of SKALP, 
containing the N-terminal transglutaminase substrate motifs in addition to the 
antiproteinase domain, were found. SKALP expression in cultured cells was found 
to be dependent on the system used. In a submerged culture system, SKALP could 
be induced by fetal calf serum. 
These findings demonstrate that SKALP is an inducible proteinase 
inhibitor and support the concept that SKALP acts as a regulatory molecule in 
cutaneous homeostasis. 
Introduction 
Human epidermis is a stratified keratinizing epithelium that follows a highly 
coordinated process of differentiation leading to a layer of dead cells, and forming the 
protective covering of the skin (for reviews, see1,2). Under pathological conditions (e.g. 
psoriasis) or during regenerative and adaptive processes (e.g. wound healing), human 
epidermis switches from the normal differentiation program to a 'hyperproliferative' 
differentiation program. This includes the expression of different sets of cytokeratins3, a 
premature expression of differentiation markers (involucrin, transglutaminase) in the 
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spinous cell layers4, and an increase of cycling cells, as measured by the expression of 
Ki-67 antigen5 A similar phenotype of keratin 16 expression and a high percentage of 
cycling cells is found in exponentially growing keratinocyte monolayer cultures In vivo, 
this hyperprohferative phenotype is usually associated with inflammatory changes in 
both the dermal and epidermal compartment This was seen in diseased skin (eg 
psoriasis) as well as m experimental models6 
Previously, we have described a new senne proteinase inhibitor (skin-denved 
antileukoproteinase, which was given the acronym of SKALP) that is also part of the 
regeneratrve/hyperproliferative phenotype79 SKALP is found in lesionai psoriatic 
epidermis, but is virtually absent in normal epidermis Initially, SKALP was shown to 
be a low molecular mass, catiomc, heat-stable protein similar to elafin, an epidermal 
proteinase ìnhibuor that was subsequently described by others10 In addition, an 
elastase-specific inhibitor that is identical to SKALP has recently been reportedin 
bronchial secretions, although the exact cellular source in vivo remains obscure11 We 
cloned and sequenced the complementary deoxyribonucleic acid (cDNA) of SKALP12, 
which proved that SKALP is identical to elafin13 We showed that SKALP, as 
expressed in cultured epidermal keratinocytes, is translated as a 12 3 kDa protem 
Cleavage of the signal peptide yields a 9 9 kDa protem that is the major form found m 
cultured cells, as was confirmed by purification and N-terminal ammo acid 
sequencing12 Recently we have been able to assign the SKALP gene to chromosome 
20, region ql2-ql314 The gene has been given the approved name of Protease 
Inhibitor, skin derived (SKALP), symbol PI3, m the Genome Data Base of the HUGO 
nomenclature committee 
SKALP inhibits at least three senne proteinases, namely human leukocyte elastase, 
porcine pancreatic elastase and human leukocyte protemase 3815 The exact biological 
function of SKALP is not known at present, although the substrate specificity for 
PMN-denved, elastolytic protemases suggests that SKALP is mvolved m regulation of 
cutaneous inflammation, or protection against PMN-dependent tissue damage 
However, it is very possible that other target enzymes (e g from the keratinocytes or 
dermal fibroblasts) exist Smce we have found that the 9 9 kDa molecule, punfied from 
cultured cells, contains multiple functional transglutaminase substrate motifs12, 
functions other than controlling protemase activity cannot be excluded 
In previous studies SKALP was descnbed biochemically81б and charactenzed at the 
protem and DNA level12 We established the cellular source and localization m psonatic 
epidermis9, and recently we found that SKALP is differentially expressed m human 
epidermal tumors17 In the present study, we have investigated the expression of 
SKALP m dynamic models for keratinocyte growth and differentiation in vivo and in 
vitro It is demonstrated that SKALP expression can be induced in normal human 
epidermis and m cultured keratinocytes 
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Materials and methods 
Chemicals 
Methoxysuccinyl-alanyl-alanyl-prolyl-valyl-7-amino-4-methyl coumarin was 
obtained from Bachern, Bubendorf, Switzerland. All reagents for sodium 
dodecylsulphate/polyacrylamide gel electrophoresis SDS-PAGE, including prestained 
markers, were obtained from Bio-Rad laboratories, Richmond, CA, USA. 
Polyvinylidenedifluoride (PVDF) membrane was from Millipore, Etten-Leur, The 
Netherlands. Low molecular mass markers used for SDS-gels, goat-anti-rabbit IgG 
biotin conjugate, avidin-alkaline phosphatase, 5-bromo-4-chloro-3-indolyl phosphate, 
nitro blue tetrazolium, isoproterenol and iododeoxyuridine (IdUrd) were obtained from 
Sigma Chemicals, St. Louis, MO, USA. Swine-anti-rabbit Peroxydase, fluorescein 
isothiocyanate-conjugated rabbit anti-mouse immunoglobulins (RAM-FITC) and mouse 
anti-IdUrd antibody were obtained from Dakopatts, Copenhagen, Denmark. Penicillin, 
streptomycin and trypsin were obtained from Gibco, Breda, The Netherlands. 
Epidermal growth factor (EGF) and hydrocortisone were from Collaborative Research 
Ine, Lexington, MA, USA. Dulbecco's minimal essential medium (DMEM) and F12 
medium were obtained from Flow laboratories, Irvine, UK. Keratinocyte growth 
medium (KGM) and bovine pituitary extract were from Clonetics, San Diego, CA, 
USA. A synthetic peptide comprising amino acid 23 to 36 of SKALP was synthesized 
by Eurosequence, Groningen, The Netherlands; at the C-terminus a cysteine residue 
was added to enable coupling to a carrier protein. The sulfo-SMCC kit and Sulfolink 
gel were obtained from Pierce, IL, USA, and anti-involucrin (rabbit) from Biomedical 
Technologies Inc., Stoughton, MA, USA. RNA zol™ В was obtained from 
Cinna/Biotex Laboratories, Inc., Houston, TX, USA, and a32PdCTP from Amersham, 
UK. The 'Living Skin Equivalent' (LSE) culture system was purchased from 
Organogenesis, Cambridge, MA, USA. 
Recombinant SKALP/elafin was a kind gift from Dr Norman Russell, ICI 
Pharmaceuticals, UK. As a probe for ribosomal 28S RNA, a 2 1 kb EcoRl/Bglll 
fragment was used (a kind gift from Dr Jan Bauman, TNO Rijswijk, The Netherlands). 
As a probe for glyceraldehyde phosphate dehydrogenase (GAPDH) a 1.1 kb Pstl 
fragment was used (a kind gift from Dr Wiljan Hendriks, Dept of Cell Biology and 
Histology, University of Nijmegen, The Netherlands). 
Skin biopsies and tape stripping 
Biopsies of normal, psoriatic and tape-stripped skin were taken under local 
anaesthesia with a keratotome. The skin samples were either fixed in buffered 4% 
formalin or stored at -20°C until use for extraction of SKALP. 
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Tape stripping of human skin is the repeated application and removal of adhesive 
tape, which produces a standardized injury of the epidermis by removal of the stratum 
corneum18 Keratotome biopsies of the stripped test sites and of normal skin were taken 
at several intervals and processed for SKALP measurement, Western blots, RNA 
extraction or histology For functional assays, the biopsies were homogenized in a 
glass-glass grinder m distilled water, and centnfuged at 8,000 g for 15 minutes After 
measurement of SKALP activity (as described below), the supernatant was 
concentrated by vacuum evaporation, and subjected to SDS-PAGE and 
lmmunoblotting 
Approval of the local medical ethical committee was obtained for all experiments 
Functional measurement of SKALP activity 
Inhibition of leukocyte elastase activity, usmg the fluorogenic substrate 
methoxysuccmyl-alanyl-alanyl-prolyl-valyl-7-amino-4-methyl coumann19, was used to 
assay SKALP In this assay SKALP activity is calculated as the percentage inhibition 
of 1 ng elastase, the amount required to reduce the elastase activity m the assay by 50% 
is defined as one unit of inhibitory activity 
Purification and N-terminal sequencing of SKALP 
SKALP was purified from psoriatic scales usmg chromatofocusing, reversed-phase 
chromatography and gel permeation chromatography, according to previously described 
methods812 N-terminal gas-phase sequencing of this material was performed by 
Eurosequence, Groningen, the Netherlands8 
Antisera 
An antiserum agamst recombinant SKALP/elafin was obtained as described 
previously9 An antiserum agamst a synthetic peptide comprising ammo acids 23 to 36 
of SKALP was prepared by coupling the peptide to chicken ovalbumin via a C-terminal 
cystein residue, using the sulfo-SMCC procedure, according to the manufacturer's 
instructions This conjugate was used for immunization of a rabbit, according to 
previously described methods8 The antiserum was affinity-punfied usmg the synthetic 
peptide coupled to Sulfolink coupling gel, according to the manufacturer's instructions 
Preimmune serum was drawn as a control The two antisera against recombinant 
SKALP/elafin and synthetic peptide gave identical staining patterns on histological 
sections A monoclonal antibody agamst involucrin was obtained as previously 
described20 
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Immunohistology 
Air-exposed cell cultures and biopsies of normal, psoriatic and tape-stripped skin, 
were fixed in buffered 4% formalin for at least 24 hours and processed for embedding 
in paraffin. Sections (5 цт) were deparaffinized, rehydrated, preincubated with normal 
swine serum and incubated with anti-SKALP/elafin serum, raised either against 
recombinant SKALP/elafin or against the synthetic peptide. After incubation with 
peroxidase-conjugated swine-anti-rabbit Ig, the sections were developed with 
aminoethylcarbazole as the chromogenic substrate. Control staining was performed as 
indicated above, substituting anti-SKALP/elafin serum with preimmune serum of the 
same animal. 
SDS-PAGE and Western blotting 
Supernatants of homogenates of cell cutures and skin biopsies were vacuum-
evaporated to dryness, dissolved in non-reducing sample buffer and subjected to SDS-
PAGE. Proteins were separated on a 16% Polyacrylamide gel, using tricine as a trailing 
ion instead of tris-glycine. Gels were blotted on PVDF membranes, and proteins were 
detected immunologically using biotinylated goat anti-rabbit IgG, avidin-conjugated 
alkaline phosphatase, 5-bromo-4-chloro-3-indolyl phosphate, and nitro blue 
tetrazolium A polyclonal rabbit antiserum raised against recombinant SKALP/elafin 
was used 
RNA isolation and Northern blot analysis 
Total RNA from cultured cells and samples of normal, psoriatic and tape-stripped 
skin were extracted with RNAzol B, as suggested by the supplier. For Northern blot 
analysis, 10 μg of total RNA was fractionated on a denaturing 1% agarose gel 
containing formaldehyde, following standard procedures21 and blotted by capillary 
transfer on a nylon membrane. After transfer, RNA was fixed to the membrane by 
ultraviolet irradiation (312 nm, 0.2 J/cm2). Hybridization was performed in phosphate 
buffer as previously described, using a 0.42 kbp PvulUEcoKl fragment of the SKALP 
cDNA clone pGESKA as a probe12. Control hybridizations for equal loading were 
performed using a human 28S ribosomal RNA probe and GAPDH probe. All probes 
were labelled with 3 2P by random priming, following standard procedures. 
Autoradiography was done for on X-Omat S film (Kodak, France) at -80°C with an 
intensifying screen 
Keratinocyte culture in the Rheinwald-Green system 
First passage human keratinocytes derived from the backs of healthy, adult 
volunteers were seeded on gamma-irradiated Swiss mouse 3T3 fibroblasts . Growth 
medium was DMEM/F12 3:1 supplemented with 0.4 μg/ml hydrocortisone, 10"6M 
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isoproterenol, 100 U/ml penicillin plus 100 ug/ml streptomycin, 6% fetal calf serum 
and, starting at day three after seeding, 10 ng/ml EGF The Ca2+-concentration in the 
medium was 2 mM Keratinocytes were grown at 37°C, 95% relative humidity and 
7 5% C0 2 Cells were harvested by trypsmization, counted and used for SKALP 
measurement, Northern blot analysis or flow cytometry Labelling with IdUrd was 
performed for 30 hours before harvesting the cells Either exponentially growing cells, 
confluent cells or cells m suspension (see below) were used 
Keratinocyte culture in suspension 
Confluent keratinocyte cultures were trypsinized and resuspended in DMEM/F12 
medium (without EGF), as described above The cell suspension was kept m a 
continuously rotating device for 48 hours, as described before23, and analysed as 
described above This procedure induces terminal differentiation, as measured by 
involucnn expression, and gives results similar to the systems previously used by 
others2425 
Keratinocyte culture in KGM 
Human keratinocytes from healthy volunteers were cultured in serum-free KGM that 
was composed of keratinocyte basal medium (KBM) with 0 15 mM Calcium, 
supplemented with 0 1 mM ethanolanune, 0 1 mM phosphoethanolamine, 0 4% bovine 
pituitary extract, 10 ng/ml EGF, 5 μg/ml insulin, 0 5 μg/ml hydrocortisone, 100 U/ml 
penicillin and 100 μg/ml streptomycm For induction of SKALP expression, cultures 
were switched at 30% confluency to KGM plus 5% fetal calf serum or KGM with 
additional Ca2+ (either 0 35 mM or 2 mM) Cells were harvested after 48 h by 
trypsmization and extracted for measurement of SKALP activity and Northern blot 
analysis 
Keratinocyte culture under air-exposed conditions 
Human keratinocytes derived from healthy individuals were first cultured using the 
Rheinwald-Green feeder technique, and subsequently seeded on de-epidermized dermis 
(DED) and grown under air-exposed conditions according to the Regnier-Prumeras 
method26 Growth medium at air-exposed conditions was Dulbecco-Vogt and Ham's 
F12 3 1 supplemented with 0 4 ug/ml hydrocortisone, 106 M isoproterenol, 5% fetal 
calf serum, 10 ng/ml EGF27 The LSE model for air-exposed culture, consisting of 
human keratinocytes seeded on a fibroblast populated collagen gel, was cultured 
according to the manufacturer's instructions 
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Immunocytochemical staining and flow cytometric analysis 
A standard indirect immunocytochemical labelling technique was used with both 
anti-involucrin and anti-IdUrd antibodies on ethanol-fixed cells. DNA staining was 
performed with propidium iodide. Flow cytometric analysis was carried out using 
previously described methods23'28. 
Results 
Expression ofSKALP in vivo 
In previous studies we have shown that SKALP is expressed in the upper suprabasal 
layers of lesionai psoriatic skin but is virtually absent in normal human skin. Here, 
removal of stratum corneum by tape stripping was used as a model for standardized 
epidermal injury in normal human skin. Fig. 1 shows a time curve of SKALP-activity in 
biopsies, measured as anti-elastase activity using a fluorimetrie assay. At 48 hours a 
peak was found, and this time point was used to characterize SKALP on Western blots 
and for detection by immunohistochemistry. 
Figure 1. Time course of SKALP induction by 
tape stripping of the skin of healthy volunteers 
(n=6). SKALP activity is given in units per mg 
skin homogenate. Maximal SKALP activity is 
seen after 48 hours, standard error is 
represented by the vertical lines at each time of 
sampling. 
" 0 50 100 150 
time (h) 
In Fig. 2 it is demonstrated that, after tape stripping, one major low molecular mass 
form of SKALP is found, in contrast with findings in psoriatic epidermis and psoriatic 
scales, which contain multiple low molecular mass forms of SKALP. In extracts of 
biopsies from normal skin only trace amounts of SKALP were detected, in accordance 
with previous findings7. N-terminal amino acid sequencing of SKALP purified from 
psoriatic scales gave 3 sequences (KGPVSTP, AQEPVKGP and VxAQxxVK) which 
correspond with SKALP fragments starting at amino acid 66, 61 and 59, respectively 
(numbering based on the 12.3 kDa translation product). The SKALP forms found in 
tape-stripped skin and in psoriatic epidermis could not be purified in sufficient 
quantities for N-terminal amino acid sequencing. 





Figure 2. Western blot of extracts from 
psoriatic scales (lane 2), normal human skin 
(lanes 4, 6 and 8), and tape-stripped skin after 
48 hours, taken from the same individuals 
(lanes 3, 5 and 7). Lanes 1 and 9: molecular 
mass markers. Staining with polyclonal rabbit 
antiserum against recombinant SKALP/elafin. 
Preimmune serum was negative with all 
samples (not shown). 
1 2 3 4 5 6 7 8 9 
Immunohistological staining of skin after repeated tapestripping revealed 2-3 cell 
layers (mainly granular cells) with cytoplasmic staining positive for SKALP (Fig. 3a). 
This pattern is similar to that found in lesionai psoriatic skin (Fig. 3b) with respect to 
the absence of SKALP staining in the basal layers; a difference with psoriatic skin is 
the absence of staining in cells of the stratum spinosum. Normal epidermis was totally 
negative (Fig. 3ci. 
Figure 3. Immunohistology of tape-stripped skin (after 48 hours), psoriatic lesionai skin, and normal 
epidermis, a. Tape-stripped skin. The staining is limited to the upper layers of the suprabasal 
compartment, which contains mainly granular cells, b. Psoriatic lesionai skin. Note that several layers of 
suprabasal spinous cells of the psoriatic lesion are positive. Basal cells are negative. Non-lesional skin 
was also negative (not shown), с Normal epidermis. No positive staining was seen in the epidermis. 
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SKALP in epidermal keratinocytes 
Fig. 4 shows the presence of a 0.8 kb messenger ribonucleic acid (mRNA) in 
biopsies taken from psoriatic skin and from normal skin 40 h after injury. Normal, 
uninjured skin is essentially negative for SKALP, even on an overloaded gel. 
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Figure 4. Northern blot of SKALP mRNA in skin biopsies and cultured keratinocytes (upper panel). 10 
μg of total RNA was loaded. In biopsies from normal skin at 40 hours after injury (lane 1 ), and in skin 
from psoriatic patients (lane 2) a 0.8 kb message was found. Normal human epidermis was essentially 
negative (lane 3) even on overloaded (50 μg RNA) gels. Keratinocytes cultured in KGM were 
essentially negative (lane 4). Addition of 1% and 5% fetal calf serum (lanes 5 and 6) induced SKALP 
mRNA, in a dose-dependent fashion. Keratinocytes cultured on a 3T3 feeder layer give a strong signal 
(lane 7) which is slightly increased when cells are cultured in suspension (lane 8). The lower panel 
shows control hybridizations to check for equal RNA loading. In lane 1-6 a probe for 28S ribosomal 
RNA was used; in lanes 7 and 8 a GAPDH probe was used. 
Expression of SKALP in submerged culture systems 
We have previously shown that keratinocytes cultured in the Rheinwald-Green 
system, using a feeder layer of irradiated 3T3 cells, produce SKALP in a high 
molecular mass form that contains both the transglutaminase substrate domain and the 
antiproteinase domain. To investigate modulation of SKALP expression, we studied 
exponentially growing cells, confluent cells and cells that were kept in suspension in 
order to induce differentiation. Fig. 5 shows the amounts of SKALP extracted from 
cells cultured under these conditions, as measured by functional anti-elastase activity. 
Under hyperproliferative conditions (high percentage of IdUrd-positive cells) a high 
amount of SKALP was found and a low degree of differentiation, as assessed by the 
percentage involucrin-positive cells using flow cytometry. Keratinocytes in suspension 
leave the cell cycle (low percentage of IdUrd-positive cells) and show a rapid induction 
of involucrin, whereas the total amount of soluble SKALP decreases. This is in contrast 
to Northern blot analysis, which showed a slight increase of SKALP mRNA in 
keratinocytes cultured in suspension (Fig. 4). The pattern of SKALP expression in this 
65 
Chapter 4 
culture system is distinct from that found in vivo where basal, proliferating 
keratinocytes are negative for SKALP and the upper suprabasal, differentiated cells 
show SKALP expression. 
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Fig. 5. SKALP activity in cultured 
keratinocytes. Amounts of soluble 
SKALP extracted from 
exponentially growing cells, 
confluent cells or from cells that 
were kept in suspension are shown 
(left hand y axis). SKALP activity is 
expressed in units per 106 
keratinocytes. Markers of 
proliferation (IdUrd) and 
differentiation (involucrin) were 
measured using flow cytometry, and 
the percentage of positive 
keratinocytes for these markers are 
shown (right hand y axis). 
Induction of SKALP expression in keratinocyte monolayers was studied in the KGM 
system, a serum-free, submerged culture system, using bovine pituitary extract as a 
source of growth factors. In KGM alone no significant SKALP expresssion was found 
either at the protein or at the mRNA level. However, addition of fetal calf serum could 
induce SKALP expression in a dose-dependent fashion, as shown in Fig. 4, at the 
mRNA level. In a functional assay more than a 10-fold increase in SKALP activity was 







0.15 mM 0.35 mM 2.0 m M 5 % FCS 
Fig. 6. Induction of SKALP 
activity in submerged 
keratinocyte cultures using 
KGM. In unsupplemented 
KGM (0.15 mM Ca2+) very 
little SKALP activity is found. 
Addition of 5% fetal calf 
serum induces SKALP, as 
measured after 48 hours, in a 
functional assay on cell 
extracts. Addition of СаСЬ up 
to 2 mM did not induce a 
significant increase. SKALP 
activity is expressed as units 
per 106 keratinocytes. 
Ca-concentration 
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As 5% serum raises the Ca2+-concentration in KGM from 0.15 mM to approximately 
0.35 mM, we tested the effect of additional Ca2+ in KGM. As shown in Fig. 6 no effect 
was noted up to 2 mM Ca2+. 
Expression ofSKALP in air-exposed culture systems 
In submerged culture systems, as described above, keratinocyte phenotype and 
functional properties are distinct from the in vivo situation in normal skin. This has 
been demonstrated for several proteins including keratins, involucrin and 
transglutaminase. The expression pattern of SKALP in these systems does not correlate 
with the in vivo patterns found in psoriasis and tape-stripped skin, where SKALP is 
found in the differentiated compartment. We therefore investigated the expression 
pattern and processing of SKALP in the 'reconstructed skin' model, which approaches 
the in vivo situation. Cultures of human epidermal keratinocytes seeded on DED were 
extracted for Western blottings and processed for immunohistology. Fig. 7 shows that 
high molecular weight forms of SKALP are present, with a predominance of the 9.9 
kDa form also found in keratinocytes in the Rheinwald-Green system. The 6 kDa form, 
which is the major form in psoriatic skin, is absent in these cultures. No change in the 
pattern of SKALP processing is seen with time. 
32.5 -~ 
14.4 — 
Fig. 7. Western blot of cultures of 
human epidermal keratinocytes 
seeded on DED. Lanes 2-6, extracts 
of five different culture conditions: 10 
days submerged; 3 days submerged 
and 7 days air-exposure; 3 days 
submerged and 5 days air-exposure; 3 
g 2 -*• days submerged and 2 days air-
exposure; 3 days submerged, 
6-2 -"*" respectively. Lane 8, an extract from 
exponentially growing keratinocytes 
in the Rheinwald-Green system. Lane 
9, recombinant SKALP/elafin. Lanes 
1 and 7, prestained molecular mass 
markers. Cultured keratinocytes 
(lanes 2-6 and 8) contain high 
molecular mass forms of SKALP 
(including the 9.9 kDa processed 
form), whereas the 6 kDa form found 
in psoriatic scales (identical to recombinant SKALP/elafin) is absent. Note that the molecular masses 
given in the text are obtained from amino acid sequencing data. These values significantly deviate from 
the values obtained on SDS-PAGE, probably because of the cationic nature of SKALP. 
Immunohistology shows that SKALP is barely detectable in submerged 
keratinocytes cultured on DED (Fig. 8a), but is moderately expressed in granular cells 
1 2 3 4 5 6 7 8 9 
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shortly after air exposure (Fig. 8b). In addition to the 'reconstructed skin' model, we 
examined SKALP expression in the commercially available LSE model, which uses a 
fibroblast-populated collagen gel as a matrix for keratinocytes. Fig. 8c shows that in 
this system SKALP is highly expressed in the upper suprabasal layers, similar to the in 




Figure 8. Immunohistology of cultures of human keratinocytes seeded on DED, and keratinocytes 
cultured on a fibroblast-populated collagen gel (LSE model), a. Culture of human keratinocytes seeded 
on DED, 10 days submerged. No significant SKALP expression was found, b. Culture of human 
keratinocytes seeded on DED, 3 days submerged followed by 3 days air-exposure. Scattered 
keratinocytes with a flattened, granular cell morphology were positive for SKALP (arrows), с LSE 
model. SKALP is highly expressed in the upper suprabasal layers, similar to the in vivo expression in 
psoriatic and tape-stripped skin; see also Fig. 3 a. and b. Bar, 50 urn. 
Discussion 
We have examined the expression of SKALP by human epidermal keratinocytes 
using in vitro and in vivo models. It is shown that a transient wave of SKALP 
expression can be induced in normal human skin by epidermal injury. One major, low 
molecular mass form is found on Western blots. Positive immunohistological staining is 
found in cells of the granular layer. In vitro, the pattern and amount of SKALP 
expression depends on the culture system used. SKALP expression in the KGM sytem 
is inducible by fetal calf serum. In all in vitro systems tested, it is mainly the high 
molecular mass forms of SKALP that are found. 
Because of its specificity for the PMN-derived proteinases, elastase and proteinase-
3, SKALP/elafin has been assigned a putative role in the control of epidermal 
inflammation710. Using cDNA cloning and N-terminal sequencing of SKALP purified 
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from cultured keratinocytes, we have shown that the molecule contains a hydrofobic 
signal peptide and an additional functional domain with multiple transglutaminase 
substrate motifs12. Removal of the signal peptide results in a mature 9.9 kDa protein, 
which is the major form in cultured keratinocytes. However, in psoriatic skin, tape-
stripped skin and in urine of psoriatic patients16, low molecular mass forms 
predominate. Whether these forms result from interaction with PMN-derived 
proteinases, or from intracellular processing by keratinocyte-derived proteinases, 
remains to be investigated. The molecular masses, as indicated in the text, refer to 
calculated molecular masses obtained from amino acid and DNA sequence analysis, 
while apparent molecular masses on SDS-PAGE and Western blots are much higher 
(see Figs 2 and 7). This anomalous behaviour on SDS-gels is probably due to the highly 
cationic nature of the molecule. 
At present it is not known which factors in vivo are responsible for SKALP 
induction. In psoriatic skin and in tape-stripped skin the expression pattern follows that 
of other differentiation-related markers such as involucrin and transglutaminase; a 
difference with these markers is the absence of SKALP in normal epidermis (at least 
epidermis of the trunk and the extremities). The expression pattern of SKALP more 
closely resembles that of cytokeratin 16, which is absent in normal epidermis but is 
induced under hyperproliferative conditions such as psoriasis, regeneration after injury, 
and in cell culture in the Rheinwald-Green system SKALP expression in cell culture 
systems was found to be strongly dependent on the model used. High amounts of 
soluble SKALP could be found in exponentially growing keratinocytes in the 
Rheinwald-Green system, whereas exponentially growing cells in KGM produced very 
low quantities of SKALP. Addition of fetal calf serum to KGM was shown to induce 
SKALP expression, both at the protein level and at the mRNA level. Obviously this 
finding does not rule out the contribution of extracellular matrix molecules from 3T3 
fibroblasts, soluble 3T3 fibroblast factors or negatively regulating factors in KGM. 
When cells cultured in the Rheinwald-Green system were kept in suspension (which 
induces terminal differentiation), the amount of soluble SKALP decreased, but no 
significant change was found at the mRNA level Low SKALP activity in differentiated 
cells was not due to crosslinking of SKALP to the insoluble fraction, since the amounts 
of both soluble and particulate SKALP activity decreased in terminally differentiating 
keratinocytes (not shown). The discrepancy between Northern blot results and the 
SKALP content of the cells could be explained by secretion of SKALP in the medium 
of the suspension cultures. However, due to interference by serum proteins we have so 
far been unable to obtain accurate SKALP measurements in the culture media. 
Using immunohistology, in the air-exposed culture systems, a moderate induction of 
expression was found in the 'reconstructed skin' model, shortly after air exposure. This 
induction was not found in Western blots of culture extracts, as shown in Fig. 7. 
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However, the Western blots were primarily performed for qualitative analysis with 
respect to SKALP processing, and not for quantification of SKALP in the culture 
extracts. Histologically the expression pattern resembled that of tape-stripped skin, 
where positive SKALP staining was found mainly in flattened, granular cells. Using 
imrnunohistochemistry, a strong expression was observed in the LSE model. Possible 
explanation could be differences in the growth state of the cells, or stimulation of 
SKALP expression by fibroblast-derived factors (such as interleukin-6). Extrapolating 
the in vitro data to the in vivo situation, we speculate that induction of SKALP after 
tape stripping or inflammation in general, could be due to plasma derived factors. This 
notion is supported by a recent report showing that during inflammation, plasma protein 
levels are strongly increased in epidermis, which is otherwise devoid of plasma 
proteins29. 
The in vivo and in vitro models described here will be used to further identify the 
factors that induce SKALP expression. This will provide relevant data on the cell 
biology of cutaneous inflammation as seen in pathological conditions (e.g. psoriasis) 
and the pathophysiology of wound healing. 
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Expression patterns of SKALP 
Summary 
We have previously described a new epidermal serine proteinase inhibitor, skin-
derived antileukoproteinase (SKALP), also known as elafin. SKALP was found to 
be absent in normal human epidermis, but can be induced in vitro and in vivo 
under hyperproliferative conditions. Here we studied the expression of SKALP in 
several types of epidermal tumors such as basal cell carcinoma, squamous cell 
carcinoma, Bowen's disease, actinic keratosis, and keratoacanthoma. Using 
immunohistochemical staining SKALP appeared to be differentially expressed in 
these tumors. Functional measurements of antiproteinase activity, and Western 
blotting of tumor extracts confirmed our findings at the histological level. In 
psoriatic epidermis and in well-differentiated squamous cell carcinoma, SKALP 
messenger RNA was demonstrated by non-radioactive in situ hybridization. We 
conclude that SKALP is a marker for abnormal or disturbed squamous 
differentiation. A possible role of SKALP in the control of tumor cell invasion is 
discussed. 
Introduction 
Deregulation of gene expression may cause transcription of oncogenes or loss of 
action of growth suppressor genes, leading to abnormal growth of tumor cells. 
However, in addition to disturbed growth control, also invasion and metastasis are 
features of malignant behavior. Several proteinases such as plasminogen activators, 
cathepsins and metalloproteinases, as well as the inhibitors of these enzymes have been 
reported to be associated with tumor invasion and metastasis1"9. Expression of 
proteinases is thought to promote the migrational capacity of cells; specific inhibitors of 
these proteinases counteract this process. Hence, the term metastasis suppressor 
proteins has been coined for these inhibitors10'11. 
Recently we described a new serine proteinase inhibitor (skin-derived 
antileukoproteinase, SKALP) which is expressed in lesionai psoriatic epidermis and in 
epidermis after injury, but is absent in normal epidermis12'13. Initially, SKALP was 
shown to be a low molecular weight, cationic, heat-stable protein, that was similar to 
elafin, an epidermal proteinase inhibitor described by others14. We have recently cloned 
and sequenced the cDNA of SKALP, which proved SKALP and elafin to be identical, 
and which showed that SKALP, as expressed in cultured epidermal keratinocytes, is 
translated as a 12.3-kd protein15. Cleavage of the signal peptide yields a 9.9-kd protein 
that is the major form found in cultured cells, as was confirmed by purification and N-
terminal amino acid sequencing15. Elastase-specific inhibitors from bronchial secretions 
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with molecular weights of 10 kd, 5 kd, and 2.5 kd as reported by Hochstrasser, Kramps 
and Sallenave respectively16"18, are biological active fragments of the same larger 
precursor molecule19. SKALP inhibits at least three serine proteinases derived from 
polymorphonuclear leukocytes (PMN), namely human leukocyte elastase, porcine 
pancreatic elastase, and human leukocyte proteinase 312·13·20. 
Recently we could assign the chromosomal localization of the SKALP gene to 
chromosome 20, band ql2-1321. The gene has been given the approved name of 
Proteinase Inhibitor, skin derived (SKALP), symbol: PI3, in the Genome Data Base of 
the HUGO nomenclature committee. The exact biological function of SKALP is not 
known at present, although the substrate specificity for polymorphonuclear cell-derived, 
elastolytic proteinases suggests that SKALP is involved in regulation of cutaneous 
inflammation, or protection against polymorphonuclear cell-dependent tissue damage 
However, it is very likely that other target enzymes (eg, from the keratinocytes or 
dermal fibroblasts) exist; hence other functions cannot be excluded. Because the 
expression of SKALP appears not to be associated with the differentiation program of 
normal epidermis but is found in differentiating cells in the context of the 
hyperproliferative differentiation program (eg, psoriasis and wound healing), we 
investigated its expression in a number of epidermal tumors that are characterized by 
abnormal differentiation The data clearly show that SKALP is differentially expressed 
in these tumors. 
We have previously shown that SKALP is absent in normal human epidermis22'23. 
This is in contradiction with the findings of Nonomura and coworkers who reported the 
focal expression of SKALP in normal human epidermis as shown with m situ 
hybridization24. Therefore we have examined normal human epidermis from many 
different locations using immunohistochemical methods, and psoriatic and non-psoriatic 
epidermis by mRNA in situ hybridization. We found strong expression of SKALP in 
psoriatic epidermis, but no SKALP could be detected in normal epidermis either by 
immunohistochemistry or mRNA m situ hybridization. 
Materials and methods 
Chemicals 
Methoxysuccinyl-alanyl-alanyl-prolyl-valyl-7-amino-4-methyl coumarin, was 
obtained from Bachern, Bubendorf, Switzerland. Cetyltrimethylammoniumbromide was 
obtained from ICI, UK. All reagents for sodium dodecyl sulfate Polyacrylamide gel 
electrophoresis (SDS-PAGE) including prestained markers were obtained from Bio-Rad 
Laboratories, Richmond, CA. Polybuffer exchanger 118, a Superdex 75 fast protein 
liquid chromatography column, a Superdex 75 PC 3.2/30 column, and a SMART 
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chromatography system were obtained from Pharmacia, Uppsala, Sweden. 
Polyvinylidenedifluoride membrane was from Millipore, Etten-Leur, the Netherlands. 
Low molecular weight markers used for SDS gels, goat anti-rabbit IgG biotin 
conjugate, avidin-alkaline phosphatase, 5-bromo-4-chloro-3-indolyl phosphate, and 
nitroblue tetrazolium were obtained from Sigma Chemicals, St. Louis, MO. Calibration 
proteins used in chromatography were obtained from Boehringer Mannheim GmbH, 
Mannheim, Germany. Recombinant elafin was a gift from Dr Norman Russell, ICI 
Pharmaceuticals, United Kingdom. 
Tissues 
For tumor specimens, material used for histology was selected from archive biopsy 
material sent for routine analysis. The specimens had been fixed in buffered 4% 
formalin for at least 24 hours, and had been embedded in paraffin. Seven basal cell 
carcinomas, seven squamous cell carcinomas, three Bowen's diseases, seven actinic 
keratoses, and seven keratoacanthomas were selected. The tissue was cut in 5-um 
sections, using a Reichert Jung rotation microtome (Leica, Rijswijk, The Netherlands), 
and mounted on slides, which were coated with 3-aminopropyltriethoxysilane. Sections 
were dried 48 hours at 37 °C. Some of the sections were used for m situ hybridization 
experiments as well. A limited amount of fresh tumor material was available for 
extraction and was used for functional measurements and Western blotting (two basal 
cell carcmomas, two keratoacanthomas and one squamous cell carcinoma). 
To obtain normal and psoriatic epidermal samples punch biopsies from adult skin 
were taken from normal human volunteers and psoriatic patients. Permission had been 
granted by the local medical ethical committee. For immunohistochemistry, biopsies 
were fixed in buffered 4% formalin for at least 24 hours, embedded in paraffin, and cut 
in 6 urn sections as described here. For m situ hybridization, tissues were frozen and 
sections (10 μπι) were prepared on a Reichert Jung 2800 frigocut N. 
Construction ofplasmid and synthesis of RNA probes 
For in situ hybridization of the tumor sections, a 0.42-kb PvulUEcoRl fragment of 
pGESKA15, containing almost complete SKALP complementary DNA, was cloned into 
the plasmid pGEM4 (Promega, Madison, WI). Sense and anti-sense complementary 
RNA probes were prepared. Briefly, after linearizing the construct with either ВатШ 
or Kpnl, the anti-sense and sense cRNAs were transcribed in vitro using digoxigenin-
labeled UTP, T7 and SP6 RNA polymerase, respectively, using a digoxigenin RNA 
labeling kit according to the manufacturer's instructions (Boehringer Mannheim, 
Germany) The cRNAs were fragmented with limited alkaline hydrolysis to reduce the 
size of the synthesized RNAs to approximately 0.2 kb25. For in situ hybridization on the 
frozen sections of normal and psoriatic epidermis, a 251 bp PCR product (bp +69 to 
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+320, relative to the translation start site) was obtained from the SKALP cDNA clone 
pGESKA, which was subcloned in a pGEM4 vector. The plasmid was linearized with 
Pstl to synthesize the antisense cRNA or in the reverse orientation the control sense 
cRNA by T7 polymerase, using the previously mentioned digoxigenin RNA labeling 
kit. These cRNAs were also fragmented by limited alkaline hydrolysis and used for in 
situ hybridization. 
In situ hybridization 
Nonradioactive m situ hybridization on tumor sections was, with some 
modifications, performed as described by Yokouchi et al26. Sections were deparaffinized 
with xylene, rehydrated using solutions of diminishing ethanol concentrations (99.8 to 
50%), and finally rinsed in phosphate-buffered saline (PBS). Sections were then treated 
with 0.01% Triton X-100 for 1.5 minutes, rinsed with PBS, incubated with pepsin 1 
mg/ml in 0.2 N HCl for 15 minutes at 37 °C, and again rinsed with PBS. Thereafter 
postfixation with 4% paraformaldehyde in distilled water was performed. After 
acetylation with 0.1 M triethylamine, pH 8.0, and 0.25% acetic anhydride for 10 
minutes, sections were rinsed with PBS and dehydrated with increasing concentrations 
ofethanol(50to99.8%). 
The hybridization mixture consisted of 50% formamide, 2x standard sodium citrate 
(SSC), 10% dextransulfate, 5X Denhard's solution (0.1% bovine serum albumin, 0.1% 
polyvinylpyrrolidone, 0.1% Ficoll 400), 10 mM dithiothreitol, 1 mg/ml E. coli transfer 
RNA, and 4 mg/ml probe. After overnight hybridization at 37 °C, the sections were 
washed twice for 45 minutes at 37 °C in 2x SSC and lx SSC, respectively, incubated 
for 20 minutes at room temperature with 20 mg/ml DNase free RNase A, (Boehringer 
Mannheim, Germany) and 50 mM NaCl in Tris EDTA. A second wash step with lx 
SSC was earned out for 30 minutes at room temperature. Hybridization signals were 
detected by an enzyme-linked immunoassay using a nucleic acid detection kit as 
suggested by the manufacturer (Boehringer Mannheim, Germany). 
For m situ hybridizations of epidermal tissues, frozen sections were mounted on 
superfrost slides (Menzel-Glazer) and heated for 2 min at 50°C. The sections were 
fixed in PBS containing 4% (v/v) paraformaldehyde for 10 min at room temperature, 
and rehydrated twice for 5 min in 2xSSC. Sections were prehybridized for at least 1 
hour in hybridization buffer consisting of 4xSSC, 10% dextrane, 50% formamide, 0.5 
mg herring sperm DNA (Boehringer Mannheim, Germany), 2 mM 
ethylenediaminetetratic acid (EDTA) and lx Denhardt's solution. Prehybridization and 
hybridization were performed at 37°C. Prehybridization fluid was drained off and the 
slides were washed in 2xSSC. Hybridization was carried out in humidity chambers 
using the probe in a concentration of 100 ng/ml hybridization buffer After overnight 
incubation, sections were washed in 2xSSC at 37°C followed by washes in 
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O.lxSSC/50% formamide 3 times for 7 min. Hybridization signals were detected using 
a Nucleic Acid Detection Kit (Boehringer Mannheim, Germany). Hybridized sections 
were processed as follows: sections were washed for 5 min in buffer I (100 mM Tris, 
150 mM NaCl, pH 7.5) at room temperature, followed by incubation in buffer I 
containing 1% blocking mix (Boehringer Mannheim, Germany) for 30 min. Anti-
digoxygenin-antibody conjugate diluted 1:200 with buffer I containing 1% blocking mix 
was applied to each section and incubated at room temperature for 2 h in a humidified 
chamber. Slides were then washed in buffer II (100 mM Tris, 50 mM MgCl, 100 mM 
NaCl, pH 9.5). A solution of 5-bromo-4-chloro-indolyl phosphate and nitroblue 
tetrazolium (Boehringer Mannheim, Germany) in buffer II was made immediately prior 
to use, filtered, and placed in a light-proof glass tray. Sections were developed 
overnight at room temperature, washed in TE (10 mM Tris, 1 mM EDTA, pH 8.0), 
counterstained with methylene green, and mounted usmg gelatin/glycerol. 
Isolation and purification ofSKALP 
Skin-derived antileukoproteinase was isolated both from psoriatic scales and from 
cultured human keratinocytes as described before12'13. In short, psoriatic scales were 
homogenized in distilled water, yielding a suspension that was boiled and centrifugea, 
followed by chloroform extraction and centrifugation. After concentration, the 
preparation was further purified by chromatofocusing (РВЕ 118 column, triethylamine 
buffer) and affinity chromatography (porcine pancreatic elastase coupled to cyanogen 
bromide-activated Sepharose 4B, phosphate-buffered saline (PBS) washing buffer, 0.1 
M acetic acid eluting buffer). Final purification was by gel permeation chromatography 
on a Superdex-75 fast protein liquid chromatography column. Extracts of cultured 
keratinocytes were prepared by sonication of the cells in distilled water and subjected to 
the SMART chromatography system (Superdex 75 PC 3.2/30 column). Anti-elastase 
activity in obtained fractions was measured; relevant fractions were pooled and vacuum 
evaporated to dryness, dissolved in nonreducing SDS-sample buffer and used for SDS-
PAGE. 
Anti-SKALP serum 
Skin-derived antileukoproteinase purified from psoriatic scales or recombinant elafin 
was used for immunization procedures as described before23. In short, a rabbit was 
immunized intracutaneously with highly purified SKALP that was partially crosslinked 
with glutaraldehyde and emulsified in Freunds complete adjuvant. A booster with the 
same preparation was given after 2 weeks, and 4 weeks later serum was collected via 
standard methods. Control (preimmune) serum was drawn before the immunization 
procedure. The specificity of the antiserum was validated on Western blots and in 
functional assays which showed 1) that the elastase-inhibiting activity could be 
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absorbed by the antiserum and 2) that the band stained on a Western blot corresponded 
with a band of anti-elastase activity eluted from the SDS-PAGE gel as shown before13 
The two antisera yielded identical Stauung patterns both in immunohistology and 
Western blotting 
Immunohistology 
Before Stauung, sections were deparaffinized with xylene, rehydrated using solutions 
of diminishing ethanol concentrations (99 8 to 50%) and finally nnsed m PBS 
Thereupon, sections were premcubated with normal swine serum 20% for 15 minutes, 
and incubated with a polyclonal rabbit antiserum against SKALP at a dilution of 1/100 
in PBS with 1% bovine serum albumin for 60 minutes After washing m PBS, sections 
were mcubated with peroxidase conjugated swine anti-rabbit immunoglobulin at a 
dilution of 1/50 in PBS with 1% bovine serum albumin and 5% human AB serum 
Subsequently, sections were washed m PBS and Na-acetate buffer and developed with 
aminoethylcarbazole as the chromogenic substrate (mcubation period, 10 minutes) 
Finally, sections were washed in distilled water, counterstained with hematoxylin and 
eosin, washed again, dried and embedded m glycerol-gelatin solution Control Stauung 
was performed as mdicated above, with polyclonal rabbit anti-SKALP serum 
substituted by preimmune serum of the same animal 
SDS-PAGE and Western blotting. 
Three types of tumors were studied (basal cell carcinoma, squamous cell carcinoma, 
and keratoacanthoma) Tumor tissue (average weight approximately 110 mg) was 
homogenized m distilled water with the help of a glass-glass grinder, whereafter the 
homogenate was centnfuged for 10 minutes at 12,000 revolutions per minute Anti-
elastase activity of the supernatant was assayed as described before1227 The clear 
supernatant was vacuum evaporated to dryness, and subsequently dissolved in 500 ml 
nonreducing SDS-sample buffer, 5ml of this preparation was subjected to SDS-PAGE 
As a reference, samples of recombinant elafin, psoriatic scale extract, and partially 
purified SKALP of cultured keratinocytes were used m the same run of electrophoresis 
Proteins were separated on a 16% Polyacrylamide gel, usmg tncine as a trailing ion 
instead of tns(hydroxymethyl)anunomethane-glycuie28 Gels were blotted on 
polyvmylidenedifluonde membranes, and immunologic detection of protems was 
performed using biotinylated goat anti-rabbit immunoglobulin G, avidin-conjugated 
alkaline phosphatase, 5-bromo-4-chloro-3-indolyl phosphate, and mtroblue tetrazohum 
Both a polyclonal rabbit antiserum raised agamst highly purified SKALP from psoriatic 
scales and a rabbit antiserum against recombinant elafin were used 
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Microphoíography 
Microphotographs were taken with a Leitz photomicroscope and a Zeiss Axiophot, 
Wetzlar and Oberkochen/Württemberg, Germany, respectively, using black-and-white 
negative film Agfapan APX 25 from Agfa-Gevaert AG, Leverkusen, Germany. 
Results 
Immunohistology 
In basal cell carcinoma, all tumor cells with a typical basaloid phenotype were 
negative with respect to SKALP expression. Cells of the granular layer in epidermis 
overlying the tumor were positive in some cases. The epidermis of distant normal skin 
did not show any SKALP expression at all (not shown). 
In squamous cell carcinoma, SKALP expression varied both between tumors and 
within the individual tumors. However, most tumors and tumor cell nests that had a 
clear squamous phenotype were strongly positive as shown in Figure 1. In all specimens 
basal cells were negative. SKALP expression was seen from the suprabasal cells 
upward, with the strongest staining in the cells just underneath the layer of the cornified 
envelopes, namely, in the stratum granulosum and the most superficial layers of the 
stratum spinosum. 
Figure 1. Immunohistology of squamous cell carcinoma, staining was performed with anti-SKALP 
antibody, (a) Cell nests with a clear squamous phenotype are strongly positive. Overlying epidermis is 
negative. Magnification: xl25. (b) Detail. SKALP staining is most distinct in cells with a granular cell 
morphology. Magnification: x313. 
83 
Chapter 5 
In Bowen's disease we found that the tumor cells showed a weak cytoplasmic 
staining, which was less pronounced than in the well differentiated squamous cell 
carcinomas (not shown). 
All biopsies from actinic keratoses were positive, with a variation both in intensity 
of SKALP expression and in the number of cell layers that were stained (two to eight 
layers, basal cells were negative; an example of an actinic keratosis with only one to 
two positive layers of keratinocytes is shown in Figure 2). 
Figure 2. Immunohistology of actinic 
keratosis. Variation in intensity of SKALP 
staining and in the number of stained cell 
layers as well, was observed. Here 
SKALP staining is limited to one or two 
layers of granular cells, just beneath 
ridges of thickened stratum comeum. 
Magnification: xl25. 
a 
Figure 3. Immunohistology of keratoacanthoma. (a) Strong SKALP staining is seen in multiple layers of 
well differentiated suprabasal cells. Magnification: xl25. (b) Detail. Note the polarized distribution of 
SKALP-staining pattern close to the upper cell membrane, in the direction of increasing differentiation, 
possibly because of cross-linking to the cornified envelope by transglutaminase. Magnification: x313. 
84 
Expression patterns of SKALP 
Keratoacanthomas were strongly positive for SKALP as shown in Figure 3. The 
staining pattern was comparable to that of the other tumors, ie, the suprabasal layers 
were stained, and staining was most pronounced in the cell layer just below cornified 
envelope formation. Staining of the stratum corneum in all positive tumors was 
inconsistent, varying both in intensity and distribution pattern from strong to nearly 
absent, and from continuous to patchy. 
We examined normal human epidermis from many different locations of the body. 
We were unable to demonstrate expression of SKALP at the protein level in adult 
epidermis from ear, breast, axilla, scrotum, mamilla, palms, and soles (results not 
shown). 
In situ hybridization 
Using cRNA probes, sections of a well differentiated squamous cell carcinoma, 
which showed high expression of SKALP using immunohistochemistry, and 
cryosections of normal human skin and lesionai psoriatic epidermis were studied for the 
presence of SKALP messenger RNA. In general, mRNA expression in squamous cell 
carcinoma colocalized with expression of SKALP at the protein level as shown on serial 
sections (Figure 4). Also, strong expression of SKALP was found in the suprabasal 
compartment of psoriatic epidermis, whereas normal epidermis was completely 
negative. All tissues were negative with the sense cRNA probes, used as controls 
(Figure 5). 
Figure 4. In situ hybridization and immunohistology on serial sections of a well differentiated squamous 
cell carcinoma. Using antisense digoxigenin labeled cRNA probes, SKALP messenger RNA is shown 
(a), and immunostaining demonstrates presence of SKALP protein (b). Note that the expression at the 
mRNA level roughly coincides with the expression at the protein level; eg, see the region indicated by 
the arrows. Magnification: xlOO. 
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Figure 5. In situ hybridization on cryosections of normal human skin and lesionai psoriatic skin using a 
digoxigenin-labeled SKALP cRNA probe. Normal skin was negative both with the antisense probe and 
the sense probe (a and b). Lesionai psoriatic skin was strongly positive in the suprabasal cells, using the 
antisense probe (c). No signal above background was obtained with the sense probe (d). The occasional 
alkaline phosphatase precipitate adjacent to the basal membrane is non-specific, and was seen both with 
the sense probe and with the antisense probe. Magnification: x313. 
Functional measurements and Western blotting 
Using a sensitive microassay12'27, both squamous cell carcinoma and 
keratoacanthoma showed inhibitory activity against human leukocyte elastase, whereas 
basal cell carcinoma was negative. Squamous cell carcinoma contained an anti-elastase 
activity of 2.3 U/mg tissue, anti-elastase activity of keratoacanthoma was 167 U/mg 
tissue, and in basal cell carcinoma no inhibitory activity was measured. Western 
blotting showed SKALP expression both in squamous cell carcinoma and in kera-
toacanthoma, but not in basal cell carcinoma (Figure 6). Interestingly, there were clear 
differences in staining patterns between the tumors. Keratoacanthoma showed one clear 
band with an apparent molecular weight of 13.6 kd. In contrast, squamous cell 
carcinoma showed four different bands with apparent molecular weights of 15.7 kd, 
15.0 kd, 13.8 kd and 12.4 kd. Basal carcinoma was negative. SKALP from cultured 
keratinocytes (apparent molecular weight about 16 kd), recombinant elafin (apparent 
approximate molecular weight 11 kd) and psoriatic scale extract were used as positive 
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controls and as a reference range for the various forms of SKALP that are known to 
exist12·13. 
32.5 — 
Figure 6. Western blot of human skin tumor 
extracts stained with a polyclonal anti-
SKALP serum. In lane 5 distinct bands were 
stained in a squamous cell carcinoma extract. 
In lane 6, only a single band is seen in an 
extract from keratoacanthoma. Lane 7 shows 
the absence of SKALP staining in a basal cell 
carcinoma extract. Partially purified SKALP 
of cultured keratinocytes, recombinant elafin, 
and psoriatic scale extract have been used as 
reference samples, and staining is shown in 
lanes 1, 2, and 4, respectively. Molecular 
weight markers (kilodaltons) are shown in 
lanes 3 and 8. 
Conclusions and discussion 
In this study we have demonstrated that the serine proteinase inhibitor SKALP is 
differentially expressed in human epidermal tumors. On immunohistology, the 
cytoplasmatic staining was mostly limited to the upper differentiating layers of the 
tumors. Basal layers were completely negative, which is in accordance with previous 
findings in psoriatic epidermis and in a model for wound healing29,30. Basal cell 
carcinomas were negative as well. In situ hybridization of well differentiated squamous 
cell carcinoma showed presence of messenger RNA in the same regions where SKALP 
protein is demonstrated by immunostaining. Also, using mRNA in situ hybridization we 
demonstrated that SKALP is highly expressed in the suprabasal compartment of 
psoriatic epidermis, whereas normal epidermis is completely negative for SKALP 
mRNA. This is in contrast with the findings of Nonomura and coworkers, who 
described the presence of SKALP mRNA in psoriatic epidermis and focal presence of 
SKALP mRNA in normal epidermis24. We do however occasionally observe SKALP 
expression near hair follicles and acrosyringia in the epidermis, which may explain the 
focal expression found by Nonomura and coworkers. 
Previous studies showed that SKALP exists in multiple forms12"14. In material from 
psoriatic patients a consistent pattern of two major bands emerges. As shown in Figure 
14.4 — 
8.2 - * 
6.2 — 
щ^^ 
^ · ^ш 
1 2 3 4 5 6 7 8 
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6, in squamous cell carcinoma and keratoacanthoma different forms of SKALP are 
found. Because only a limited number of fresh tumors was available to us, it is not clear 
whether these patterns are specific for a type of tumor. The antisera used in this study 
were polyclonal rabbit antisera against recombinant elafin or SKALP purified from 
psoriatic scales. These sera yielded identical staining patterns on Western blots and in 
immunohistology. Both sera were raised against SKALP fragments that contained the 
anti-proteinase activity, which is located in the C-terminal half of the mature SKALP 
molecule. Because the different forms of SKALP are generated by various N-terminal 
deletions, all these cleavage products are recognized by these antisera. As can be seen in 
Figure 6, the apparent molecular weights of SKALP obtained on SDS-PAGE 
significantly deviate from the calculated molecular weights (as mentioned above). This 
is probably caused by the strong cationi с nature of the molecule (isoelectric point = 9.6) 
which causes a slower migration in this electrophoresis system. 
At present there are no conclusive data on the biological significance of SKALP in 
human skin. However, previous studies suggest that the expression of SKALP in vivo is 
linked to inflammatory processes. We have shown that SKALP-activity is found in 
epidermis from inflammatory skin diseases and that it is absent in normal skin and m 
non-inflammatory skin diseases31. Recently we have found that SKALP is secreted in 
urine of psoriatic patients and that the levels found roughly correlate with the severity 
of the disease32. In addition we have found that SKALP can be induced in normal 
human skin as a result of standardized injury by tape stripping12,30. These findings show 
that SKALP is induced in human skin under inflammatory conditions, which suggests 
(but not proves) that SKALP could act as a negative feedback on the inflammatory 
response. Whether this would be at the level of interference with migration of 
polymorphonuclear cells/monocytes or as a protective mechanism against tissue damage 
remains to be investigated. Apart from this ideological interpretation, SKALP 
expression can also be regarded as part of the regenerative/hyperproliferative 
differentiation program of human epidermis as seen in psoriasis and wound healing. 
The normal differentiation program includes the expression of keratin 1 and 10, the 
absence of keratin 6 and 16 in the suprabasal layers, and expression of differentiation-
related proteins (eg, filaggrin, involucrin, transglutaminase) exclusively in the stratum 
granulosum33. The differentiation program of the regenerative/hyperproliferative type is 
characterized by the induction of keratin 6 and 16, down-regulation of keratin 10, 
premature expression of differentiation-related proteins and, as we have shown, the 
induction of SKALP. Within the context of this differentiation program, SKALP could 
function as an inhibitor of proteinases from inflammatory cells or could, speculatively, 
be directed to keratinocyte-derived proteinases to control other, hitherto unknown 
processes. Evidence that SKALP expression is coupled to the 
regenerative/hyperproliferative phenotype is further supported by the notion that 
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cultured keratinocytes, which are also negative for keratins 1/10 and positive for 
keratins 6/16, produce large amounts of SKALP12,15. 
In this study we demonstrate that SKALP expression is high in tumors with a clear 
squamous phenotype, and is absent in poorly differentiated squamous cell carcinomas 
and m basal cell carcinomas. Tumor cells display disturbed differentiation programs 
that are distinct from the differentiation programs mentioned above. Speculatively, loss 
of expression of anti-proteinase activity could promote tumor cell migration, invasive 
growth, or induce detachment of tumor cells. This could be caused either by proteinase 
activity from the tumor cells or by proteinases derived from neighbouring cells (stroma, 
inflammatory cells). The finding in the present study that SKALP expression is low or 
absent in the tumors that are able to invade the dermal connective tissue is in line with 
this hypothesis. 
In general, little is known with respect to the role of other proteinases and proteinase 
inhibitors in normal human skin It has been suggested that cathepsin D is involved in 
transglutaminase processing34. Both urokinase-type plasminogen activator and its 
inhibitor, plasminogen activator inhibitor were demonstrated in human epidermis35"37, 
and are supposed to be involved in keratinocyte migration38,39. Expression levels of 
proteinases and proteinase inhibitors have been reported to correlate with tumor 
proliferation, tissue invasion and tissue destruction. The resulting tissue destruction 
would be caused by a local imbalance between proteinases and their inhibitors7,40^5. 
Recently the presence of urokinase-type plasminogen activator in squamous cell 
carcinoma and the absence in basal cell carcinoma was described, with the interesting 
finding that those squamous cell carcinomas that were lacking urokinase-type 
plasminogen activator were histologically well differentiated tumors37,46. 
Because not a single factor but cascades and combinations of different events are 
important in carcinogenesis, it is interesting to speculate on a possible role of SKALP 
in this process. SKALP may interfere with elastolytic activity that tumor cells need to 
penetrate the dermal tissue either directly by inhibiting elastase47,48 or indirectly through 
interference with an elastase-dependent pathway of plasminogen activation49. In 
addition, SKALP might inhibit unknown proteinases and interfere with proteolysis in an 
elastase-independent way. Therefore, within the spectrum of keratoacanthoma, actinic 
keratoses and squamous cell carcinomas with varying degrees of differentiation, a 
progressive loss of SKALP expression could facilitate invasive growth. To date, a 
correlation between tumor aggressiveness and the expression of lytic enzymes such as 
heparanases, plasminogen activators, cathepsins, and metalloproteinases has been 
described750. Furthermore, it has been shown that inhibitors of metalloproteinases or 
inhibitors of serineproteinases can block tumor cell invasion1,51,52. Most likely a panel of 
different enzymes and inhibitors will determine the migrational behavior of tumor cells, 
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Summary 
Skin-derived antileukoproteinase (SKALP), otherwise known as elafin, is an 
epidermal proteinase inhibitor directed against leukocytic enzymes. SKALP is 
absent in normal skin but is expressed under inflammatory conditions, and is 
putatively involved in regulation of cutaneous inflammation. Here we report on the 
regulation of SKALP gene expression in an in vitro system using cultured human 
keratinocytes. It is shown that under serum free conditions SKALP cannot be 
detected at the protein level in submerged cultures of human keratinocytes. 
Addition of 5% fetal calf serum or human serum induces cells with a differentiated 
phenotype that are positive for involucrin and SKALP, as assessed with 
immunocytochemistry. In order to better appreciate this regulation at the 
molecular level, the gene's start site of transcription was mapped and a 1 kb 5'-
upstream region of the SKALP gene was cloned. Several potentially regulating 
elements could be identified, including consensus sequences for factors that are 
known to be involved in inflammatory responses, such as NF-IL6 and NF-KB. 
Deletion fragments of the 1 kb 5'-upstream region, fused with the luciferase 
reporter gene were used for transfection experiments in different cell types. We 
show that the SKALP promoter region is active in epidermal keratinocytes and not 
in skin fibroblasts, A431 cells, and glioblastoma cells. Although the 1 kb fragment 
used in the transfection experiments appeared to be keratinocyte-specific, it was 
not stratum-specific since the promoter was equally active in keratinocytes forming 
a monolayer of undifferentiated cells. 
Introduction 
Human epidermis is mainly composed of keratinocytes, which follow a highly 
coordinated process of terminal differentiation This process, which is well balanced in 
normal human skin, leads to the forming of a protective layer of dead corneocytes ' 
Under pathological conditions (eg psoriasis) or during regenerative processes (eg 
wound healing) the epidermis switches from its normal differentiation program to a 
hyperproliferative differentiation program As a result of this, activated phagocytes 
such as polymorphonuclear leukocytes (PMNs) are found m the dermis and, to a lesser 
extent, in the epidermis These cells can release several proteinases such as cathepsm G, 
proteinase 3, collagenase, and elastase3, proteinases which have also been implicated in 
several pathological conditions, such as lung emphysema4, glomerulonephritis5, 
arthritis6, and certain inflammatory skin diseases78 The senne proteinase elastase is 
active at neutral pH and can degrade a broad range of connective tissue components 
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such as elastin9, proteoglycans10, and collagen". The action of elastase and other 
proteinases is controlled by systemic proteinase inhibitors (e.g. alpha-1-PI) and by 
locally produced proteinase inhibitors such as secretory leukocyte proteinase inhibitor12. 
We have previously reported a new serine proteinase inhibitor which was named skin-
derived antileukoproteinase (SKALP)1314. SKALP has also been described by others as 
elafin15 and elastase-specific inhibitor (ESI)16. We have characterized SKALP at the 
molecular and cell biological level1718 (for a recent review see Molhuizen and 
Schalkwijk19) and showed that in cultured human keratinocytes, SKALP is translated as 
a 12.3 kDa precursor molecule containing a signal peptide. Cleavage of this signal 
peptide yields a mature protein with a molecular mass of 9.9 kDa. Apart from the 
proteinase inhibiting domain this molecule contains an additional domain with multiple 
functional transglutaminase substrate motifs17. Recently we have been able to assign the 
SKALP gene to chromosome region 20ql2-ql320 and the SKALP gene was given the 
approved name oí Protease Inhibitor, skin derived (SKALP) and the symbol PI3. 
SKALP is highly expressed in psoriatic epidermis and is inducible in vivo using tape 
stripping, a model for standardized injury of the epidermis18'21,22. Furthermore we found 
that SKALP is differentially expressed in human epidermal tumors23. In cultured 
normal human keratinocytes SKALP expression can be induced by the addition of fetal 
calf serum (FCS) in a dose-dependent fashion18. Although the exact biological function 
of SKALP is presently not well understood, the substrate specificity for PMN-derived 
elastolytic proteinases suggests that SKALP plays a role in the regulation of cutaneous 
inflammation, or acts as a protective agent against phagocyte-dependent tissue damage. 
It is however very well possible that other target enzymes exist. Also, in view of the 
presence of the transglutaminase substrate motifs, functions other than controlling 
proteinase activity can not be excluded. In order to further elucidate the regulation of 
SKALP gene expression we have determined the transcription start site of the SKALP 
mRNA, subcloned and sequenced the human SKALP gene promoter region, and 
functionally characterized this region via fusion of different promoter fragments to a 
reporter gene and transfection into various cell types We show that the SKALP gene 
promoter is active in human epidermal keratinocytes and not in human skin fibroblasts, 
A431 cells (from an epidermoid carcinoma cell line), and glioblastoma cells. The 1 kb 
fragment used in the transfection experiments did, however, not contain the sequence 
specificity which would restrict its expression to differentiated keratinocytes. 
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Experimental procedures 
Isolation and cloning of the human SKALP gene promoter region 
We previously reported the cloning of a 9 kb Hindlìì genomic fragment which was 
characterized as containing the human SKALP gene20. From this clone an EcoRUXbal 
fragment containing approximately 1 kb promoter region in addition to a small part of 
the first exon was cloned into a pBluescript KS+ vector (Stratagene) following standard 
procedures24. The resulting clone was designated pSPR029. From this clone, 
ЕсоШ/Bglll and XbaVBgñl fragments were further subcloned and both strands were 
sequenced by means of the dideoxy chain termination method25 using standard 
sequencing primers and nested primers. DNA sequence gel readings were edited and 
analyzed using the Fragment Assembly System package (Genetics Computer Group, 
Inc.) on a UNIX computer (Silicon Graphics Systems) as provided by the Dutch 
CAOS/CAMM Center. 
Nuclease SI mapping of the SKALP mRNA transcription start site 
To determine the transcription start site of the SKALP mRNA, we used a single-
stranded DNA probe in a nuclease SI mapping procedure. To obtain a single-stranded 
DNA probe we cloned a BgliUXbal fragment (pos. -436 to +62, Fig. 1) in a 
ХЬа ВатШ-digested pBluescript KS+ vector. This subclone was used for 
transformation of XL 1-Blue cells (Stratagene). From a single colony containing the 
appropriate clone, 2 ml of TYP/Amp broth (16 g Bacto-tryptone, 16 g Bacto-yeast 
extract, 5 g NaCl, and 2.5 g K2HP04 per liter with ampicillin, 50 ug/ml) was inoculated 
and incubated (37°C, 250 rpm). The next day 100 μΐ of this culture was used to 
inoculate 5 ml TYP/Amp broth. After 30 min 40 μΐ of an M13K07 helper phage stock 
(5xl010 pfu) was added, and the culture was grown overnight. The following day single-
stranded DNA was isolated according to standard procedures24. To prepare a 
radiolabeled probe, T7 primer (50 ng) was hybridized to 250 ng single-stranded DNA 
and primer extension was performed with 5 U T7 DNA polymerase (Pharmacia) in the 
presence of 4 μΐ 32PdCTP (specific activity: 370 Mbq/ml) in 30 μΐ reaction mix 
containing 0.4 mM dATP, 1.3 μΜ dCTP, 0.4 mM dGTP, and 0.4 mM dTTP. After 15 
min incubation at 37°C, 2 μΐ 10 mM dCTP and 5 U T7 DNA polymerase were added, 
followed by an additional incubation for 15 min at 37°C. The reaction was terminated 
by incubation at 65°C for 10 min followed by digestion with EcoRi for 2 h at 37°C to 
remove the entire insert. After complete digestion, DNA was denatured by boiling for 5 
mm and separated on a 4% denaturing Polyacrylamide gel. The radiolabeled probe 
DNA was isolated from the gel. 
The RNA used in this experiment was isolated from cultured human keratinocytes, 
which were grown to confluency and induced for SKALP gene expression by addition 
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of 5% fetal calf serum, as described elsewhere in this chapter For hybridization of the 
probe, 50 μ§ total RNA was mixed with 8xl05 cpm single-stranded probe DNA, 
precipitated, and washed once with 70% ethanol For control, yeast tRNA was used 
The pellet was resuspended in 30 μΐ hybridization buffer containing 40 mM PIPES 
(piperazine-N,N'-bis[2-ethanesulfonic acid]) pH 6 4, 1 mM EDTA 
(ethylenediaminetetraacetic acid) pH8 0, 0 5 M NaCl, and 80% formamide, and 
incubated for 10 mm at 85°C, followed by overnight mcubation at 50°C After probe-
hybndization, 300 μΐ nuclease SI reaction mix (280 mM NaCi, 5 mM NaAc pH 4 5, 
4 5 mM ZnS04, 20 pg/ml denatured herring sperm DNA, and 1000 U/ml nuclease SI 
(Pharmacia)) was added and the reaction was incubated at 37°C for 60 mm As a 
control reaction to check for sufficient nuclease S1 activity, free radiolabeled probe was 
also subjected to nuclease S1 digestion The nuclease S1 reactions were terminated by 
addition of 80 μΐ SI stop buffer (4 M №ЦАс, 50 mM EDTA pH 8 0, and 50 μg/ml 
yeast tRNA), followed by precipitation The pellets were washed with 70% ethanol, 
dried, resuspended m 3 μΐ H 20, and mcubated at 65°C for 5 min Formamide loading 
buffer (4 μΐ) was added, and the samples were boiled for 4 mm and chilled on ice to 
denature the DNA The samples were separated on a 8% Polyacrylamide gel, and 
autoradiography was performed using Kodak X-Omat 100 x-ray film 
Construction of promoter-lucij'erase fusion genes 
A 1 kb promoter fragment (-1012/+13 m Fig 1) was synthesized by PCR usmg our 
genomic SKALP DNA clone pSPR029 as a template Two primers were used to 
introduce a Smal site and a Ncol site at the 5'- and 3'-terminus of the PCR-product 
respectively The primers used were, forward 5'-GAATTCCCCGGGTTCATATAT-
3' (directed agamst position -1012/-993) and reverse 5'-
TGCTGGCCCÇCATGGTGTCA-3' (directed agamst position -8/+13) The PCR 
product was subcloned mto a pGEM-4 T-vector26 and sequenced for verification From 
this clone a 1 kb SmaVNcol fragment (position -1007/+3) was directionally subcloned 
m frame with the firefly luciferase gene in pSLA4, a modified pSLA3 vector27, directly 
connected to the ATG of the luciferase gene through the Ncol site The resulting clone 
was designated pSPL/1012 From this clone deletion mutants were derived, designated 
pSPL/440, pSPL/290, pSPL/170 and pSPL/130 All constructs were prepared with 
standard cloning techniques24 using available restriction sites, exept clone pSPL/130 
To generate this clone we used a mutagenic forward pnmer 5'-
GGTGGATATCTCCCAATAC-3 ' in a PCR reaction with the previously mentioned 
reverse pnmer to introduce an EcoRV site at position -129 From the resultmg PCR 
product an EcoRV/Ncol fragment was cloned m a SmaVNcol digested pSLA4 vector 
Also, a construct containing the SKALP insert from clone pSPL/1012 (the largest 
fragment) in the reverse orientation, designated pSPLrl012, was generated To obtain 
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this clone, the previously mentioned 1 kb SmaVNcol fragment was used. A blunt end 
was generated at the Ncol site, and the complete fragment was subcloned in the Smal 
site from the pSLA4 vector, thus maintaining the original translation start site from the 




- 9 3 7 TAAAATATGTTAATAGACCAGACCAAGTCTCACACACAACACACACACACACACTCACACACACACACACACACA 
- θ 6 2 CACACCCCTACCTGTGGTCAGGGGTCAGGCTTTCATGATTAGCAGTCCCCATTAGACTCACAAGTTGATGGTTCA 
-7 θ 7 AAGAGACAACAATTCTTCACAAGAAACAGGGTGCTGTTCAAAGAAGTGGGGAGGCATGCTGGACACACACACTGT 
-712 AGATGTCCAATGTATACATGATACATGTTTTCTACTACTTTCTGATTATTTTCTCCCTACCACTGTGATTTCAAG 
-6 3 7 GGCATCATCCCTCTTCAGACCTAGAATTCCACCTTCCAATTACTTTCTTGATGCATCTGAAAGGCCGTCTCTGAA 
- 5 62 ACAGCAAAGTGCAATAATTAGTCATTATGTATTCAAGGCAAATTTGTCTTACAGAGTTTTTTGCAGGACCAGGGA 
pSPL/440 
Φ 
- 4 В 7 AGAAGGAAGGAAATGCCCAGTTTGATGCTGGGAGTGGTAAAATGATAAAGTAGATCTGGGTGGGGTTTGTAGCAC 
NF-IL6 NF-IL6 AP-1 
- 412 CAGAGCATAATGGAGAAACACCTTGGTTTTGTAATCAAGACTGGATCTACCAGTGACTTGCTGAATAACCTTCGG 
pSPL/290 
Φ 




Φ AP-1 NF-IL6 NF-KB Φ 




- 3 7 ATGGCCrrAGCTCTTAGCCAAACACCTTCCrGACACCATaAGGGCCAGCAGCTTCTTGATCGTGGTGGTGTTCCT 
• • φ M R A S S F L I V V V F L 
-19 -16 -13 
39 CATCGCTGGGACGCTGGTTCTAGA 
I A G Τ L V L 
Figure 1 Nucleotide sequence of the human genomic clone pSPR029 encoding the human SKALP 
gene promoter region Numbering is in relation to the first base of the ATG translation start codon at 
position +1 The borders of the fragments used for the luciferase constructs are marked with arrows 
(Φ) The putative "CAAT" and "TATA" boxes are double underlined and the proposed imperfect 
"TATA" box is printed m italics and double underlined The putative transcription start sites are 
marked with bold arrows (φ) The translation start codon is printed m bold face Binding sites for 
possible regulatory elements are underlined 
Cell cultures and DNA transfections 
Human skin fibroblasts from healthy volunteers, glioblastoma cells, and A431 cells 
were cultured in 6 well culture dishes m Al medium, composed of DMEM/F12 (Flow 
Laboratories, Irvine, Scotland) supplemented with 0 4 ug/ml hydrocortisone 
(Collaborative Research Ine Lexington, MA, USA), 10 ng/ml epidermal growth factor 
(EGF) and 10б M isoproterenol (Sigma, St Louis, MO, USA), 100 îu/ml penicillin 
plus 100 μg/ml streptomycin (Gibco BRL, Breda, The Netherlands), and 10% FCS 
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(Seralab, Nistelrode, The Netherlands) Human keratinocytes from healthy volunteers 
were cultured m 6 well culture dishes m Keratinocyte Growth Medium (KGM) 
composed of Keratinocyte Basal Medium (KBM, Clonetics, San Diego, CA, USA) 
containing 0 15 mM calcium, supplemented with 0 1 mM ethanolamine (Sigma, St 
Louis, MO, USA), 0 1 mM phosphoethanolamine (Sigma, St Louis, MO, USA), 0 4% 
bovine pituitary extract (ΒΡΕ, Clonetics, San Diego, CA, USA), 10 ng/ml EGF, 5 
μ^ητί insulin, 0 5 μg/ml hydrocortisone and 100 ι u/ml penicillin, plus 100 ug/ml 
streptomycin For mduction of SKALP gene expression, cultures were switched at 
100% confluency to KGM plus 5% FCS Human skin fibroblasts, glioblastoma cells, 
and A431 cells were grown at 37°C, 95% humidity and 8% C0 2 m air Keratinocytes 
were cultured m 5% CO2 m air For ïmmunohistochemical staining, cells were cultured 
under the same conditions, on round tissue culture cover slips (Thermanox, Miles 























Figure 2 Schematic representation of the luciferase constructs containing deletion fragments from the 
promoter region of the SKALP gene 
For transfection, cells were grown to confluency Prior to transfection, the cells were 
washed twice with 1 ml KBM or DMEM/F12 (both without serum and antibiotics) for 
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keratinocytes or fibroblasts, glioblastoma cells, and A431 cells respectively, and then 
900 μΐ KBM or DMEM/F12 was added Mixes with 4 |og plasmid DNA (3 μg 
promoter-luciferase fusion construct and 1 μ% CMV-ß-Gal) and 8 μΐ lipofectin (Gibco 
BRL, Breda, The Netherlands) were prepared m a final volume of 100 μΐ KBM or 
DMEM/F12, incubated for 20 min at room temperature, and added to the cell cultures, 
followed by incubation under standard culture conditions After 6 hr 1 ml KGM or Al 
medium was added to the cultures The next day the medium was aspirated and the cells 
were mcubated in fresh KGM or Al medium for another 24 hr Plasmid CMV-ß-Gal, 
which contains the Escherichia coli y9-galactosidase gene driven by the cytomegalovirus 
promoter, was used m each transfection as an internal control 
Luciferase and ß-galactosidase assay 
Prior to harvesting, cells were washed twice with phosphate buffered salme (PBS) 
Then 150 μΐ reporter lysis buffer (Promega, Madison, WI, USA) was added After 15 
min cells were collected usmg a rubber policeman and disrupted by somcation 
Luciferase assays were performed usmg 40 μΐ cell lysate with 100 μΐ luciferase assay 
substrate buffer (Promega, Madison, WI, USA) on a luminometer (LKB Wallac 1250) 
Measurements were registered on a 1-channel recorder (LKB Bromma 2210) 
Luciferase activity was expressed as mV/ml cell extract To assay ß-galactosidase we 
used 4-Mu-ß-D-galactoside (Sigma, St Louis, MO, USA) as a fluongenic substrate 
Briefly, 5 μΐ cell extract was diluted 20-fold m water and 100 μΐ 1 mM 4-Mu-ß-D-
galactoside in assay buffer (2 mM MgCl2 and 50 mM dithiothreitol m 1 M phosphate 
buffer) was added The reactions were 10 mm mcubated at 37°C Measurements were 
performed on a spectrofluorophotometer (model RF-5001PC, Shimadzu Europe GmbH, 
Duisburg, Germany) usmg Xex=360 nm and Xem=450 nm ß-galactosidase activity was 
expressed m Fluorescence Units (FU) per μΐ cell extract 
Immunohistochemical staining 
Cells grown on cover slips were fixed m 1% paraformaldehyde m PBS for 10 mm 
at room temperature (RT), followed by mcubation for 4 min m 96% methanol and for 2 
min in acetone subsequently, both at -20°C The cover slips were then air-dried (room 
temperature) and mounted to glass slides Samples were stored at -20°C until further 
use For immunohistochemical staining, fixed cells were mcubated with gentle agitation 
in 50 mM NH4CI m PBS for 15 mm at RT The samples were premcubated m 20% 
Normal Goat Serum (Vector Laboratories) in PBS (10 nun, RT) Incubation with the 
primary antibody was done for 60 mm at 37°C The antiserum against SKALP was 
obtained as described earlier22 A monoclonal antibody agamst mvolucnn was also 
obtained as described before28 After mcubation with the primary antibody, the samples 
were incubated m biotinylated goat anti rabbit IgG (Vecta Stam) for 30 mm at 37°C 
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Incubation in biotin/avidin solution was for 30 min at 37°C, followed by 10 min 
incubation at RT in diaminobenzidin (DAB) as the chromogenic substrate. Finally, 
haematoxylin and eosin staining was carried out on all samples. After all of the above 
steps, samples were washed in PBS (15 min, RT). 
RNA isolation and Northern blot analysis. 
Total RNA from cultured cells was extracted with RNAzol В as suggested by the 
supplier (Cinna/Biotex Laboratories, Inc., Houston, TX, USA). For Northern blot 
analysis, 10 μg of total RNA was fractionated on a 1% agarose gel (dissolved in 10 
mM sodium phosphate buffer pH 7.0) following standard procedures24. Briefly, 10 μg 
RNA was dissolved in sample buffer (10 mM sodium phosphate, 1.25 M glyoxal, 45% 
DMSO [dimethyl sulfoxide]). The samples were incubated for 60 min at 50°C and 
cooled on ice. Prior to loading, samples were supplemented with gel loading buffer 
(50% glycerol, 10 mM sodium phosphate buffer pH 7.0, 0.25% bromphenol blue, 
0.25% xylene cyanol). Gels were run in 10 mM sodium phosphate buffer, pH 7.0. The 
pH of the electrophoresis buffer was kept within acceptable limits by constant 
circulation of the buffer. The gels were blotted by capillary transfer on a nylon 
membrane in lOxSSC (1.5 M sodium chloride, 0.15 M sodium citrate). After transfer, 
membranes were washed in 2xSSC and RNA was fixed to the membrane by ultraviolet 
irradiation (312 nm, 0.2 J/cm2). Equal loading and RNA integrity were assessed by 
ethidium bromide staining of the membrane. Hybridization was performed in phosphate 
buffer as previously described, using a 0.42 kbp PvulVEcoKl fragment of the SKALP 
cDNA clone pGESKA as a probe17. The probe was labeled with 32P by random 
pruning, following standard procedures. Autoradiography was done for 16 h on X-
Omat S film (Kodak) at -80°C with an intensifying screen. 
Results 
Expression of SKALP in differentiating keratinocytes 
In normal human epidermis SKALP expression is absent, and in psoriatic epidermis 
SKALP is exclusively expressed in the suprabasal cells. In psoriatic skin the expression 
pattern resembles the pattern found for involucrin and transglutaminase which are both 
strongly upregulated and prematurely expressed. In a previous study we showed that 
SKALP expression could be induced in cultured keratinocytes by the addition of FCS18. 
Since we intended to use this culture system for transfection experiments in promoter 
studies, we wanted to characterize the cell population which is responsible for SKALP 
expression. To this end we performed immunohistochemical staining of the 
keratinocytes cultured on cover slips. As demonstrated in Fig 3, cells positive for 
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SKALP displayed a differentiated phenotype, i.e. they were large polygonal cells on top 
of a basal layer consisting of relatively small, SKALP-negative cells. Addition of 5% 
FCS induced a strong increase in the number of these cells compared to keratinocytes 
cultured in KGM alone, which form a monolayer of SKALP-negative cells. To confirm 
the differentiated phenotype of these cells, staining for the cornified envelope precursor 
protein involucrin was performed. As can be seen in Fig. 3, involucrin-positive cells 
were morphologically similar to the SKALP-positive cells. In addition to FCS we also 
investigated whether human serum can induce SKALP. Using 5% normal human serum 
in KGM as an induction medium we found similar results as for 5% FCS. For practical 
reasons, in all subsequent experiments FCS was used for induction of SKALP 
expression. In a previous study we showed that several other cell types (including blood 
cells, endothelial cells, melanocytes, and A431 cells) were negative for SKALP13. In 
this study we used A431 cells (from epithelial origin), skin fibroblasts and glioblastoma 
cells (both from mesenchymal origin) to study the cell specificity of SKALP expression. 
In Fig. 4, Northern blot analysis shows that these cells are indeed negative for SKALP. 
•щЩ 
Figure 3. Keratinocytes grown on cover slips, a. Cells grown in KGM without FCS, stained with anti-
SKALP. b. Cells grown in KGM without FCS, stained with anti-involucrin. с Cells grown in KGM 
supplemented with 5% FCS, stained with anti-SKALP. d. Cells grown in KGM supplemented with 5% 




Figure 4. Northern blot analysis of SKALP 
expression in different cell types. Lane 1: 
keratinocytes grown in in KGM. Lane 2: 
keratinocytes grown in KGM supplemented with 
FCS. Lane 3: human skin fibroblasts. Lane 4: 
glioblastoma cells. Lane 5: A431 cells. 
Determination of the SKALP mRNA transcription start site 
Both SKALP cDNA and the SKALP gene were cloned in our laboratory as well as 
by others17'20·29,30. The transcription start site of the SKALP mRNA however, was not 
determined sofar. We initially tried to determine the transcription start site by primer 
extension and by PCR, both on reverse transcribed mRNA from cultured human 
keratinocytes, but these approaches were unsuccessful. Here, we performed nuclease SI 
mapping on RNA from cultured human keratinocytes with a single-stranded SKALP 
DNA probe. As a negative control, yeast tRNA was used as a substrate in the same 
procedure. See also Fig. 5. The SI nuclease reaction did not yield one single band, as 
shown in Fig. 5, but a number of positive bands. Three prominent bands suggesting 
major transcription start sites were found at positions -19, -16 and -13 respectively, 
relative to the translation start site in Fig. 1. This was found both at 45°C and at 50°C. 
Figure 5. Results of the nuclease 
SI mapping experiments. The 
three major transcription start 
sites in lane В are marked with 
arrows. The control reaction 
containing the radiolabeled probe 
* with tRNA in lane A is negative, 
except for one faint band (*) 
* 
І 
which was found in all the 
reactions, and hence cannot 
indicate a transcription start site. 
As a molecular weight marker 
(M), a sequencing reaction was 
used. 
Μ A В 
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Sequence and activity of the SKALP gene promoter region 
The possible SKALP gene promoter region was first identified in the genomic 
sequence on the basis of the presence of both a putative CAAT box and a putative 
TATA box29'30 at positions -121 and -94 relative to the first base of the translation 
initiation codon (Fig. 1). Computer-assisted analysis of this promoter region revealed 
the presence of several potential regulatory elements, based on homology with 
consensus sequences. Two AP-1 binding sites are found at positions -351 and -176, 
and binding sites for Sp 1 and AP-2 are found at positions -80 and -69 respectively. One 
binding site for NF-κΒ is present at position -163, and four NF-IL6 like binding sites 
are found at positions -402, -386, -203, and -166 (Fig. 1). 
To define regions necessary for promoter activity, several truncated promoter-
luciferase fusion gene constructs were tested in transfection assays. A 1 kb promoter 
fragment (nt -1012 to +3 in Fig. 1) was cloned in-frame with the luciferase gene in the 
promoterless pSLA4 vector to form clone pSPL/1012. Four deletion clones, pSPL/440, 
pSPL/290, pSPL/170 and pSPL/130 as well as the 1012 bp clone in the reverse 
orientation, pSPLrl012, were constructed and these clones were used for lipofectin-
mediated transfection into cultured human keratinocytes as described. Luciferase 
activity was high in keratinocytes transfected with clone pSPL/1012 and virtually non-










pSPL/130 pSPL/170 pSPL/290 pSPL/440 pSPU1012 pSPLM012 
deletion clones 
Figure 6. Expression of the luciferase gene under the control of different fragments from the SKALP 
gene promoter region. Closed bars represent luciferase signals obtained from the keratinocyte cultures 
induced with FCS. Open bars represent the signals from the non-induced cultures. For all constructs 
except pSPL/1012 the error bars indicate the range of 2 measurements. The error bars in pSPL/1012 
represent the standard error of 6 (+FCS) and 5 (-FCS) measurements respectively. 
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Deletion of region -1012/-440 resulted in a 90% reduction of the luciferase signal. 
Subsequent deletion of the regions -440/-290 and -290/-170 had no significant effect on 
the luciferase signal, but deletion of region -170/-130 resulted in a further decrease of 
the luciferase signal (see Fig. 6). 
Clone pSPL/1012 was also used for transfection into human fibroblasts, 
glioblastoma cells, and A431 cells. No luciferase signal could be detected in extracts 
from the fibroblasts and A431 cells transfected with this clone, which means that the 
luciferase signal in these cells is below the detection level (0.05 mV).The transfection 
method used here is less efficient for fibroblasts and A431 cells than for keratinocytes. 
Transfection of the CMV-ß-Gal vector in human fibroblasts resulted in twentyfold 
lower signals compared to human keratinocytes. In A431 cells these signals were 
approximately fortyfold lower. The maximum luciferase signal obtained from 
keratinocyte extracts after transfection with clone pSPL/1012 averages 22.2 mV, which 
is approximately 440 times the minimum detection level. Thus, after normalization, the 
luciferase signal in keratinocytes is at least a factor 20 higher than in fibroblasts and a 
factor 40 higher than in A431 cells. Transfection of the reverse orientation clone 
pSPLrl012 gave no detectable signals in these cells. Transfection of clone pSPL/1012 
in glioblastoma cells resulted in a luciferase signal just above the detection level, 
whereas clone pSPLrl012 gave no detectable signal. For comparison the average 





Figure 7. Average luciferase signals from construct pSPL/1012 in different cell types. 1: keratinocytes 
cultured in the presence of FCS (bar: standard error of 6 measurements); 2: keratinocytes cultured 
without FCS (bar: standard еітог of 5 measurements); 3: glioblastoma cells; 4: A431 cells; 5: fibroblasts 
(bars: range of 2 measurements). Note that the scale is drawn logarithmically. 
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Discussion 
SKALP is an epidermal proteinase inhibitor which is expressed in the 
hyperprohferative/regenerative differentiation program which is found in psoriasis, 
wound healing and some epidermal tumors181923 Studying the regulation of SKALP 
expression could generate insight m the complex mechanisms of both epidermal 
differentiation and regulation of cutaneous inflammation 
As mentioned previously, experiments to determine the transcription start site by 
primer extension and by PCR failed for reasons which are not yet clear Perhaps, 
secondary structures may be present m the SKALP mRNA, which could restrict the 
action of the reverse transcriptase used m the pnmer extension experiments The use of 
a thermostable reverse transcriptase could help to overcome this problem Here we tried 
to determine the SKALP mRNA transcription start site usmg a nuclease S1 mapping 
assay Three putative major transcription start sites could be identified at positions -19, 
-16, and -13 respectively (Fig 1) These results are surprising because such short 
mRNA leader sequences are quite unusual In yeast, certain genes (nbosomal protein 
genes) have a shorter than average mRNA leader length (25 nucleotides) ranging from 
15 to 46 nucleotides, and from one gene (MATal) the mRNA has a leader sequence 
which is only 11 nucleotides long31 It is known however, that the leader sequences on 
most vertebrate mRNAs fall m the range of 20 to 100 nucleotides3233 Therefore, our 
results should be interpreted with caution, and additional experiments, such as primer 
extension experiments with thermostable reverse transcriptase, will be performed If our 
present results are correct, this would imply that the TATA box at position -94 relative 
to the translation start site (Fig 1) could be non-functional because its distance to the 
transcription start site is to large Alternatively, our results could indicate that another 
(nontypical) TATA box is used m the SKALP gene At position -48, (Fig 1) we found 
a sequence, TAAAGA, which might serve as the actual TATA box The distance of this 
TAAAGA sequence to the transcription start sites we determined (29, 32, and 35 
nucleotides respectively) is well m accordance with the consensus, and it is known that 
such TATA-hke sequences can serve as actual TATA boxes34 The fact that this 
sequence does not show a perfect match to the consensus sequence for TATA boxes 
(TATA[A/T]A[A/T]) could also explam the existence of multiple transcription 
startpoints3536 
In order to mvestigate SKALP expression in more detail at the molecular level we 
have used an m vitro model with human epidermal keratinocytes which allows a timed 
induction of the molecule We show that the endogenous SKALP gene is expressed m a 
cell-specific manner At the protein level SKALP is only found in differentiated 
keratinocytes, whereas fibroblasts, glioblastoma cells, and A431 cells are negative for 
SKALP, which was also confirmed at the mRNA level (Fig 4) Deletion analysis of the 
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SKALP promoter region suggests a role for several potentially regulating elements. The 
shortest promoter construct, containing the most proximal promoter region (130 bp) 
containing both the putative CAAT box and the putative TATA box as well as the 
TAAAGA sequence, shows low but still significant promoter activity. In this region 
consensus sequences for the binding sites of two common transcription factors, Spi and 
AP-2 are present. Both binding sites are found within a very short stretch of 19 bp. 
(pos.-80/-62, Fig. 1), which is well ahead of the transcription start sites. Construct 
pSPL/170 contains a consensus sequence for a binding site for NF-KB and a NF-IL6-
like binding site in addition to the possible sites for Spi and AP-2. Additional NF-IL6-
like sites are present in construct pSPL/290 (1 site) and pSPL/440 (2 sites). These 
contructs also both contain a possible binding site for AP-1. Compared to clone 
pSPL/130, the promoter activity of clone pSPL/170 is further increased, suggesting a 
stimulatory role for NF-IL6 and/or NF-κΒ. It is remarkable that both transcription 
factors have been shown to play an important role in the regulation of genes involved in 
inflammatory processes, immune response, and acute phase reaction37-38. As mentioned 
before, SKALP is thought to play a role in regulation of cutaneous inflammatory 
processes. The presence of region -170/-290 in clone pSPL/290 causes no increased 
promoter activity, and also with construct pSPL/440, containing two additional NF-
IL6-Iike sites and one AP-1 site, no increase increase in promoter activity is seen, 
compared to construct pSPL/170. Promoter activity is further significantly increased in 
construct pSPL/1012. Based on this observation, we speculate that in region -440/-
1012 one or more enhancer elements may be present. This is currently under 
investigation. In summary, we conclude that the 1 kb 5'-upstream region of the SKALP 
gene, which we used in the experiments described here, can function as a promoter for 
the SKALP gene, and that important regulatory elements may be present in region -
170/+1. Furthermore, our results suggest that region -1012/-440 may contain one or 
more enhancer elements. 
In the culture system using KGM as a medium for exponential growth we usually 
find that the majority of the cells is SKALP-negative. However, once the cultures reach 
confluency, some endogenous SKALP expression is seen. Close microscopic 
examination of these cells shows that a minor subpopulation of the keratinocytes in 
these cultures switches to a differentiated phenotype, expressing SKALP as shown in 
Fig. 3. Also at the mRNA level, a weak SKALP signal can be seen in cells cultured in 
KGM alone (Fig. 4). It is only after addition of FCS that a significant number of cells 
in this culture system turn to terminal differentiation. However, with the promoter 
constructs used in the transfection assays described here, we always find a detectable 
luciferase signal, even in the unstimulated cultures (without FCS), except for construct 
pSPSrl012 containing the promoter region in the reverse orientation, which was always 
completely negative. Addition of FCS results in increased luciferase activity for all 
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constructs (except for pSPLrl012), suggesting that the enhanced promoter activity we 
observe is not exclusively caused by sequence-specific factors. As judged from the ß-
galactosidase values obtained in these experiments (data not shown), it seems that in the 
culture system we used, addition of FCS also caused a slight increase of the 
transcription activity in general. Our results suggest that the 5'-upstream region used in 
the experiments described here does not contain all the elements involved in the 
regulation of stratum-specific expression of the SKALP gene in vivo. Possible 
negatively regulating elements may be present further upstream of the 1012 bp 
fragment used in these experiments, or in the intron sequences or the 3'-flanking region 
of the SKALP gene. 
Together with SKALP, several other proteins are specifically expressed in cutaneous 
disorders that show a hyperproliferative differentiation program. Two keratin genes, 
CK6 and CK 16 are exclusively expressed in hyperproliferative keratinocytes, and are 
therefore usually referred to as hyperproliferation-associated keratins39. Regulation of 
expression of the keratin genes has been extensively investigated in the past few years. 
For the CK 16 gene it was found that the transcriptional activity of the promoter 
depends on at least five different keratinocyte nuclear transcription factors, including 
Spi and AP-2, and it has been suggested that AP-2 and Spi may participate together in 
the transcriptional switch from differentiation- to activation-specific keratins40. The 
presence of possible binding sites for these factors in the SKALP promoter region is in 
favour of this suggestion. 
Very recently a study was published by Zhang et alM in which the regulation of 
expression of elafin (identical to SKALP) mRNA in normal mammary epithelial cells 
and in breast tumor cells is described. They found that, at the mRNA level, normal 
breast cells consistently express elafin at a high level, whereas most carcinoma-derived 
cells showed little or no elafin expression. Although they show that expression of the 
elafin gene is regulated at the transcriptional level, they do not confirm elafin expression 
at the protein level. Deletion analysis of the promoter region of elafin revealed both a 
positive and a negative regulatory element, and the positive regulatory element was 
found to be important for constitutive expression of elafin mRNA in normal breast 
cells Furthermore, they showed that, in their culture system, expression of elafin is 
subject to cell cycle regulation The gene is dramatically down-regulated in S phase, 
and the inhibition is released in G2. This study by Zhang et al. did not establish the 
transcription start site, and the cDNA that they cloned from human epithelial cells only 
extends to 13 nucleotides of the 5'-untranslated region. 
Future experiments will be aimed at a more detailed knowledge of the regulation of 
SKALP gene expression SKALP is expressed in cells which are committed to 
hyperproliferative and/or regenerative differentiation programs. Therefore, a better 
understanding of the regulation of SKALP gene expression will add to our general 
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knowledge of regulation of differentiation. Also, since SKALP is highly abundant in 
psoriatic epidermis, insight in the regulation of SKALP expression may contribute to a 
better understanding of the mechanisms involved in the pathophysiology of 
inflammatory conditions in epithelia in general, and of psoriasis in particular. 
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Summary - Samenvatting 
Summary 
The aim of the work described in this thesis was the molecular cloning and 
characterization of the human cDNA and the corresponding gene encoding the senne 
proteinase inhibitor SKALP as well as cell biological and molecular biological studies 
on the regulation of expression of this gene in human keratinocytes A short overview of 
this work is presented m this chapter 
Chapter 1 gives a general introduction to this thesis Several aspects of cutaneous 
inflammation are described and the role of protemases and their inhibitors in 
inflammation is discussed It is now generally thought that proteinases and proteinase 
inhibitors play an important role in several pathologic conditions including 
inflammation and tumor metastasis The proteinase inhibitor skin-denved 
antileukoproteinase (SKALP) was initially found as a low molecular weight protein in 
inflamed epidermis A short overview of the knowledge on the biochemical aspects of 
SKALP at the start of this project is presented and the aim of this thesis is outlined 
there 
In chapter 2 the purification of the SKALP protein and the isolation and 
characterization of the corresponding cDNA usmg cultured human keratinocytes is 
described It is shown that SKALP is synthesized as a precursor molecule of 117 ammo 
acids, with a calculated molecular mass of 12 3 kDa This protein contains three 
domains The first domain is a signal sequence with a length of 22 amino acids The 
presence of this sequence suggests that translation of SKALP-coding mRNA takes 
place at the rough endoplasmic reticulum The signal peptide directs the newly 
synthesized protein across the membrane of the endoplasmic reticulum Once the 
protem is translocated the signal peptide is removed and the mature protein of 95 ammo 
acids (9 9 kDa) becomes part of the secretory pathway of the cell The second domain 
contains four regions that can act as substrate for transglutaminase We showed that 
SKALP can become cross-linked to protems extracted from the corrufied envelopes of 
human keratinocytes by transglutaminase, usmg these regions This finding suggests 
that m VÌVO SKALP may not only exist as the low molecular weight form we already 
knew, but also as an immobilized high molecular weight protem, attached to the 
cornified envelopes by transglutaminase cross-linking The third domain shows 40% 
homology with the carboxytemunal part of antileukoproteinase, another protemase 
inhibitor which is also described as secretory leukocyte protemase inhibitor Based on 




In chapter 3 the isolation and characterization of the human SKALP gene and its 
chromosomal localization are described. The same gene was isolated independently by 
two other groups, and the collective data available are reviewed in this chapter. The 
human gene encoding SKALP spans more than 2.6 kb, containing three exons and two 
introns. Two consensus sequences known to play an important role in the regulation of 
gene expression, a "CAAT box" and a "TATA box", are found in the 5'-region. 
Furthermore, we describe a dinucleotide repeat polymorphism in the 5'-upstream region 
of the SKALP gene. To establish the chromosomal localization of the human SKALP 
gene, our DNA clones were used for Southern blot analysis of a panel of human-
hamster hybrid cell lines and for non-radioactive in situ hybridization on chromosome 
spreads. Using these methods we could assign the SKALP gene to 20ql2-ql3, a region 
on the long arm of human chromosome 20. 
Chapter 4 deals with the expression of SKALP in dynamic models for keratinocyte 
growth and differentiation in vivo and m vitro. To study expression of SKALP m vivo 
we removed the cornified layer of the epidermis of healthy volunteers by tape stripping 
as a model for standardized epidermal injury. At several time intervals skin biopsies 
were taken, which were investigated using biochemical and immunohistochemical 
methods. It was shown that after epidermal injury a transient wave of SKALP 
expression is induced. In this model one major low molecular mass form of the SKALP 
molecule is found. This is in contrast with findings in psoriatic epidermis and psoriatic 
scales, where multiple low molecular mass forms of SKALP are found. 
Immunohistochemical staining of repeatedly tapestripped skin revealed 2-3 SKALP 
positive cell layers in the granular layer of the epidermis. Several keratinocyte culture 
systems were used to study modulation of SKALP expession in vitro. We found that 
the pattern and amount of SKALP expression depends on the culture system used. In 
the so called KGM system expression of SKALP can be induced by fetal calf serum. In 
all m vitro systems tested we mainly found the high molecular mass form of SKALP. 
Parallels of SKALP expression to expression of differentiation markers in keratinocytes 
are discussed, and it is speculated that induction of SKALP expression may be due to 
plasma-derived factors. 
In chapter 5 we describe our studies on the expression patterns of SKALP in human 
epidermis and in epidermal tumors. We examined normal human epidermis from many 
different locations using immunohistochemical methods, and psoriatic and non-psoriatic 
epidermis by mRNA m situ hybridization. We found strong expression in psoriatic 
epidermis, but no SKALP could be detected in normal epidermis. Proteinases and their 
inhibitors are known to play a role in tumor proliferation, invasion, and metastasis. 
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Therefore we studied SKALP expression m several epidermal tumors We found that 
SKALP is differentially expressed in the tumors we studied SKALP was present m 
squamous cell carcinoma, in Bowen's disease, in keratoacanthoma, and in actinic 
keratosis, but not in basal cell carcinoma The absence of SKALP m basal cell 
carcinoma conforms to our histological findings in psoriasis and wound healing, where 
SKALP is not found in basal cells 
Chapter 6 describes the characterization of the SKALP gene promoter region Part 
of the 5'-upstream region of the SKALP gene was subcloned to analyze regulation of 
expression at the molecular level Several deletion fragments of this subclone were 
fused with the firefly luciferase reporter gene and used for transfection experiments We 
transfected our constructs m human keratinocytes in which SKALP gene expression can 
be induced by addition of fetal calf serum, and in human skin fibroblasts, A431 cells 
(an epidermoid carcmoma cell line), and glioblastoma cells We show that the SKALP 
gene promoter region is highly active m human epidermal keratinocytes, and not m the 
other cell types we tested We found several potentially regulating elements in the 
SKALP gene promoter region To determine the transcription initiation site of the 
SKALP mRNA we performed nuclease SI mapping experiments We found multiple 
transcription start sites, all located very close to the translation start site 
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Samenvatting 
Het hoofddoel van het werk dat wordt beschreven in dit proefschrift was het 
doneren en karakteriseren van het humane cDNA en het daarbij behorende gen voor de 
senne proteinase remmer SKALP, alsmede het verrichten van celbiologische en 
moleculair-biologische studies met betrekking tot de regulatie van expressie van dit gen 
m humane keratinocyten In dit hoofdstuk wordt een kort overzicht gegeven van dat 
werk 
Hoofdstuk 1 geeft een algemene inleiding bij dit proefschrift Er worden diverse 
aspekten besproken met betrekking tot ontstekingen in de huid, en de rol van 
Proteinasen en hun remmers bij ontstekingen wordt belicht Tegenwoordig wordt 
aangenomen dat protemasen en proteinaseremmers een belangrijke rol spelen bij 
verschillende condities waaronder ontsteking en tumor metastasenng De 
proteinaseremmer "skin-denved antileukoproteinase" (SKALP) werd m eerste instantie 
aangetroffen als een laagmoleculair eiwit (6 kDa) m ontstoken huid In dit hoofdstuk 
wordt een kort overzicht gegeven van de biochemische eigenschappen van SKALP die 
bekend waren voor aanvang van het werk dat m dit proefschrift wordt beschreven, en de 
doelstellingen van het onderzoek worden besproken 
Hoofdstuk 2 beschrijft de opzuivenng van het SKALP eiwit en de isolatie en 
karaktensatie van het daarvoor coderende cDNA, gebruik makend van gekweekte 
humane keratinocyten We konden aantonen dat SKALP wordt gesynthetiseerd als een 
precursor molecuul van 117 aminozuren, met een molecuulgewicht van 12,3 kDa Dit 
eiwit bevat drie domemen Het eerste domem is een signaalpeptide met een lengte van 
22 aminozuren De aanwezigheid van dit signaalpeptide suggereert dat de vertaling van 
mRNA dat voor SKALP codeert, plaatsvindt aan het ruw endoplasmatisch reticulum 
Het signaalpeptide zorgt ervoor dat het meuw gesynthetiseerd eiwit wordt 
getransporteerd over de membraan van ruw endoplasmatisch reticulum Als het eiwit 
eenmaal de membraan gepasseerd is wordt het signaalpeptide verwijderd Het 
resterende "rijpe" eiwit, bestaande uit 95 aminozuren (9,9 kDa), kan vervolgens door de 
cel worden uitgescheiden Het tweede domein bevat vier geconserveerde gebiedjes die 
kunnen fungeren als substraat voor het enzym transglutaminase We toonden aan dat 
SKALP middels deze gebiedjes door transglutaminase gekoppeld kan worden aan 
eiwitten die onderdeel zijn van de verhoornde laag van humane keratinocyten Dit 
suggereert dat SKALP m vivo niet alleen voorkomt als het laagmoleculaire eiwit dat we 
al kenden, maar dat het tevens kan bestaan als een geimmobiliseerd hoogmoleculair 
eiwit dat aan de verhoornde bestanddelen van keratinocyten is gekoppeld Het derde 
domein komt voor 40% overeen met het carboxyterminale deel van antileukoproteinase, 
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een andere proteinaseremmer, die tevens is beschreven als "secretory leukocyte 
proteinase inhibitor". Op grond van deze opvallende overeenkomst wordt het derde 
domein aangemerkt als het proteinaseremmende deel dat reeds bekend was. 
In hoofdstruk 3 worden de isolatie en karakterisatie van het humane SKALP gen en 
de chromosomale lokalisatie daarvan beschreven. Het zelfde gen werd tevens 
onafhankelijk door twee andere groepen geïsoleerd, en in dit hoofdfstuk wordt een 
overzicht gegeven van de gezamenlijke gegevens. Het humane SKALP gen omvat meer 
dan 2,6 kb en bestaat uit drie exons en twee introns. In het 5'-gebied bevinden zich twee 
consensus sequenties, een zogenaamde "CAAT-box" en een "TATA-box", waarvan 
bekend is dat ze een belangrijke rol spelen bij de regulatie van genexpressie. Om de 
chromosomale lokalisatie van het SKALP gen te bepalen hebben we onze DNA clonen 
gebruikt voor Southern blot analyse van een panel van mens-hamster hybride cellijnen 
en voor in sito hybridisatie op chromosoompreparaten. Met behulp van deze methoden 
waren we in staat om het SKALP gen toe te wijzen aan regio 20ql2-ql3, een gebied op 
de lange arm van chromosoom 20. 
Hoofdstuk 4 heeft betrekking op onderzoek dat werd gedaan aan de expressie van 
SKALP in dynamische modellen voor groei en differentiatie van keratinocyten in vivo 
en in vitro. Om de expressie van SKALP in vivo te bestuderen werd bij gezonde 
vrijwilligers de verhoornde laag van de epidermis verwijderd met behulp van plakband 
(strippen), een model voor standaard-verwonding van de epidermis. Daarna werden op 
verschillende tijdstippen huidbiopten genomen, die werden onderzocht met behulp van 
biochemische en ïmmunohistochemische methoden. We konden aantonen dat na 
verwonding van de epidermis de expressie van SKALP door keratinocyten tijdelijk 
verhoogd is. In dit model wordt voornamelijk één laagmoleculaire vorm van het SKALP 
molecuul aangetroffen. Dit is niet in overeenstemming met onze bevindingen in 
psoriatische huid en huidschilfers van psoriasispatiënten. Daarin worden meerdere 
laagmoleculaire vormen van SKALP aangetroffen. Na immunohistochemische kleuring 
van herhaaldelijk gestripte epidermis bleek dat in de granulaire laag van de epidermis 2 
á 3 cellagen positief waren voor SKALP. Om de modulatie van SKALP expressie in 
vitro te bestuderen werden verschillende kweeksystemen voor keratinocyten gebruikt. 
Het expressiepatroon en de hoeveelheid SKALP bleken afhankelijk te zijn van het 
gebruikte kweeksysteem. In het zogenaamde KGM kweeksysteem kan de expressie van 
SKALP worden geïnduceerd door toevoeging van serum. In alle in vitro systemen die 
we getest hebben vonden we voornamelijk de hoogmoleculaire vorm van SKALP. De 
analogie tussen de expressie van SKALP en enkele eiwitten die uitsluitend tot expressie 
komen in gedifferentieerde keratinocyten wordt besproken, en er wordt gespeculeerd dat 
de induktie van SKALP expressie wellicht afhankelijk is van plasmafaktoren. 
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In hoofdstuk 5 beschrijven we de studies die we verricht hebben met betrekking tot 
de expressiepatronen van SKALP in humane epidermis en m epidermale tumoren We 
hebben normale humane epidermis van een groot aantal verschillende plaatsen op het 
lichaam onderzocht met behulp van ïmmunohistochemische methoden Psoriatische en 
met-psonatische epidermis hebben we onderzocht met behulp van mRNA m situ 
hybridisatie We vonden sterke SKALP expressie in psoriatische epidermis, maar we 
konden geen SKALP expressie aantonen m normale epidermis Het is bekend dat 
Proteinasen en proteinaseremmers een rol spelen bij de processen als proliferatie, 
invasie en métastase van tumoren Daarom hebben we gekeken naar de expressie van 
SKALP in diverse epidermale tumoren Het bleek dat SKALP differentieel tot expressie 
komt in de door ons bestudeerde tumoren SKALP kon worden aangetoond in sommige 
huidtumoren zoals keratoacanthoma en plaveiselcelcarcinoom In het 
basaalcelcarcinoom bleek SKALP met aanwezig te zijn, wat in overeenstemming is met 
onze bevindingen m psoriasis en wondgenezing, waar we ook geen SKALP vinden m de 
basale cellen 
Hoofdstuk 6 beschrijft de karaktensatie van het promotergebied van het SKALP 
gen Een deel van het 5'-gebied van het SKALP gen werd gesubcloneerd om de 
regulatie van expressie op moleculair niveau te analyseren We doneerden verschillende 
deletiefragmenten voor het luciferase reporter-gen en we gebruikten de resulterende 
constructen voor transfectie-expenmenten De constructen werden getransfecteerd m 
keratinocyten waann SKALP expressie gemduceerd kan worden door toevoegmg van 
serum Verder werden de constructen getest in humane fibroblasten, A431 cellen (een 
epidermoide carcinoom cellijn), en ghoblastomacellen We tonen aan dat het 
promotergebied van het SKALP gen voornamelijk aktief is in humane epidermale 
keratinocyten, en niet in de andere celtypen die we onderzocht hebben We vonden 
verschillende potentieel regulatoire elementen in het promotergebied van het SKALP 
gen Verder worden m dit hoofdstuk de nuclease S1 mappingsexpenmenten beschreven 
die we hebben uitgevoerd om de transcriptie startplaats van het SKALP mRNA te 
bepalen We vonden diverse transcriptie startplaatsen vlakbij de translatie startplaats 
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Een promotie doe je niet alleen. Tijdens de vier jaar die ik bezig ben geweest met 
mijn promotie-onderzoek heb ik van veel mensen medewerking en steun gekregen. In het 
algemeen wil ik iedereen heel hartelijk danken die op wat voor manier dan ook een 
bijdrage heeft geleverd aan de totstandkoming van dit proefschrift. Zonder anderen 
tekort te willen doen is het me een genoegen een aantal mensen hier met name te kunnen 
bedanken. 
Allereerst wil ik hier Dr. Joost Schalkwijk bedanken. Joost, als projektleider was je 
de afgelopen vier jaar voor mij een geweldige begeleider. Je hebt me de grootst 
mogelijke vrijheid gegeven die een OIO zich naar mijn idee kan wensen, terwijl je er 
toch altijd op de juiste momenten was om mij bij te sturen als ik wat dreigde af te 
dwalen. Daarnaast was je niet 'alleen maar begeleider'; ook als mens en collega was je 
waardevol voor mij. Bedankt voor het vertrouwen, de begeleiding en de steun tijdens 
mijn promotie-periode. 
Verder wil ik mijn beide promotoren, Prof. Dr. Peter van de Kerkhof en Prof. Dr. Bé 
Wieringa, bedanken. Allereerst Peter, op verschillende manieren heb je een zeer 
essentiële bijdrage aan mijn promotie geleverd. Je belangstelling en enthousiasme voor 
mijn werk heb ik steeds als zeer inspirerend ervaren. Ook was je verantwoordelijk voor 
het scheppen van de randvoorwaarden die nodig waren voor het opstarten van een 
moleculair-biologische onderzoekstak binnen de afdeling Dermatologie. Het was een 
waar genoegen om bij jou op de afdeling te werken. Bedankt! En Bé, de eerste ?nderhalf 
jaar van mijn promotie-onderzoek heb ik uitgevoerd bij jou op de afdeling, Celbiologie 
en Histologie. Die periode is voor mij erg waardevol geweest. De wil je hartelijk 
bedanken voor de gastvrijheid en voor je bijdragen, de eerste anderhalfjaar zeer direkt, 
later wat meer op afstand maar toch altijd aanwezig als het nodig was. 
De wil ook alle anderen van Celbiologie bedanken die mij op wat voor manier dan 
ook hebben geholpen. De doel daarbij niet alleen, maar wel vooral op de mensen van lab 
65, en in het bijzonder Jan Schepens, wiens praktische kennis en nuchtere blik me veel 
waard waren. Ook aan Dr. Wiljan Hendriks heb ik veel te danken. Wiljan, bedankt voor 
het geduld en de tijd die je steeds weer nam om mee te piekeren over SKALP. 
Veel dank ben ik ook verschuldigd aan Patrick Zeeuwen. Patrick, gedurende drie 
jaar hebben we intensief met elkaar samengewerkt aan SKALP. Je bijdrage aan het 
werk in dit proefschrift is groot, en ik ben je daarvoor dankbaar! Maar daarnaast was je 
vooral ook een vriend, en ik wil je daarom ook bedanken voor de vele gezellige uren 
binnen en buiten het werk. Samen hebben we veel gerookt, gedronken, 'slappe klets 
opgehangen' en vele 'Canasta-nederlagen' geleden (daar moeten we toch eens wat aan 
veranderen). 
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Frank Laagland en Simone Hoogakker, die als studenten scheikunde een stage bij 
mij hebben gelopen, en Diana Melchers die haar afstudeerstage voor het HLO bij mij 
liep, wil ik bedanken voor hun inzet en medewerking Ondanks het feit dat we nog 
steeds geen recombinant full-length SKALP hebben, en ook geen muize-homoloog, 
waren jullie bijdragen van essentieel belang1 
En dan natuurlijk mijn kamergenoten bij Dermatologie eerst alleen Hans 
Alkemade, later ook Patrick Zeeuwen en Ivonne van Vlijmen Bedankt voor de geweldig 
leuke tijd die we met z'n allen hebben gehad m 'de achterste kamer'1 De laatste paar 
maanden werd de plaats van Hans ingenomen door Rolph Pfundt Zelden heb ik iemand 
zo snel zien integreren (of moet ik adapteren zeggen )' Rolph, het was me een 
genoegen nog een paar maanden met je te hebben kunnen samenwerken Ik wens je veel 
succes met de voortzetting van het moleculair-biologisch onderzoek aan SKALP' 
Gijs de Jongh wil ik hartelijk bedanken voor zijn hulp en instrukties bij de 
keratinocyten-kweken en de ELISA's, en voor zijn vaak relativerende opmerkingen 
Fred van Ruissen, kei als je bent met de PC, bedankt voor de hulp met allerlei PC-
probleempjes, maar vooral ook voor je geweldig collegiale instelling' Ook Piet van Ε φ 
en Jan Boezeman wil ik bedanken, vooral (maar zeker met alleen') voor hun werk als 
systeembeheerders 
Van de afdeling Anthropogenetica wil ik Prof Dr Ad Geurts van Kessel en Danielle 
Olde Weghuis heel hartelijk bedanken voor hun bijdragen aan hoofdstuk 3 Zonder jullie 
hulp zou dit hoofdstuk aanzienlijk korter geworden zijn' 
Minstens zo belangrijk als de mensen op het werk was en is het thuisfront Annette, 
jou wil ik heel hartelijk bedanken voor je begnp, steun, en vertrouwen Zonder jou was 
dit proefschrift er misschien ook wel gekomen, maar het zou dan toch zeker veel 
moeilijker geweest zijn En last but not least pa en ma, jullie wil ik ontzettend bedanken 
voor het feit dat jullie me in de gelegenheid stelden (en stimuleerden') te studeren, maar 




Henri Molhuizen werd geboren op 24 juni 1963 in het Brabantse Vlijmen, waar hij 
het grootste deel van zijn jeugd doorbracht. Na de lagere school doorliep hij zijn 
middelbare schoolperiode op HAVO 'De Naulande' in Drunen, waar hij in 1981 zijn 
diploma behaalde. In september van dat jaar startte hij zijn studie Biologie en 
Huishoudkunde aan de Nieuwe Leraren Opleiding (NLO) op het Mollerinstituut in 
Tilburg, het begin van een periode die vooral werd gekenmerkt door belangstelling voor 
de veldbiologie en zwerftochten door Griekenland. Van september 1985 tot januari 
1986 liep hij in het kader van zijn afstudeeronderzoek voor de NLO een 
wetenschappelijke stage bij de vakgroep Vergelijkende en Fysiologische Psychologie 
van het Psychologisch Laboratorium aan de Katholieke Universiteit Nijmegen (Dr. 
E.L.J.M, van Luijtelaar). Het was in deze periode dat zijn belangstelling voor 
wetenschappelijk onderzoek werd gewekt. In 1986 behaalde hij zijn akte van 
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Ziekenhuis Nijmegen. Op 11 oktober van dat jaar trouwde hij met Annette Bergmans. 
Tot 1 mei 1995 heeft hij gewerkt aan het onderzoek dat ten grondslag ligt aan dit 
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behorende bij het proefschrift 
MOLECULAR AND CELL BIOLOGICAL 
CHARACTERIZATION OF THE SERINE 
PROTEINASE INHIBITOR SKALP 
Henri Molhuizen, Nijmegen, 14 december 1995 
1 Skin-derived antileukoproteinase (SKALP) is een zowel m vivo als 
m vitro induceerbare serine proteinaseremmer die een belangrijke 
rol lijkt te spelen bij de instandhouding van de homeostase in de 
huid Dit proefschrift 
2 De conclusie van Nonomura el al. (J Invest Dermatol 103,88-91, 
1994) dat SKALP mRNA in normale epidermis tot expressie komt 
is mogelijk ingegeven door de incidentele focale expressie van 
SKALP in de nabijheid van haarfollikels Dit proefschrift 
3 Het tot op heden ontbreken van een bruikbaar diermodel voor 
SKALP-deficientie vormt een serieuze belemmering in het 
onderzoek naar de exakte biologische funktie van SKALP 
4 De eenvoud en veelzijdigheid van de genetische code wordt wellicht 
slechts benaderd door de Morse code 
4 Uit zuiver financieel oogpunt dreigt een academische promotie voor 
steeds meer promovendi in toenemende mate een slechte investering 
te worden 
6 Het wetenschappelijk onderzoek op de Nederlandse universiteiten 
wordt in de nabije toekomst steeds minder vaak zuiver 
wetenschappelijk, en steeds vaker toegepast van aard 
7 Het op legale wijze en eventueel onder medische begeleiding 
verstrekken van hard drugs aan ernstig verslaafden kan een 
belangrijke bijdrage leveren aan het terugdringen van de 
criminaliteit 
8 All travel is circular (Paul Theroux, The Great Railway Bazaar) 
9 Travel, for too long, has been trivialized in the popular press and by 
the promoters of popular tours, it deserves better It is an enduring 
subject of human concern, the essential requisite for a civilized life, 
perhaps the most effective tool for reducing foolish national pride 
and promoting a world view (Arthur Frommer, New World of 
Travel) 
10 Het zien duurt een seconde, de gedachte blijft voor altijd (Uit 
"Blauw", De Scene) 



